Browse Month: February 2017

Experienced Healthcare and Pharma Agency #arch #pharma

#pharma agency



With a team who have worked both client and agency side over many years we have. read more


With a team who have worked both client and agency side over many years we have deep experience in consumer health, pharmaceuticals and medical devices. We really understand how healthcare professionals and patients act and think, and we know how to connect them with our clients, especially online. It’s rare in Australia to find a digital agency that really gets Healthcare, or a Healthcare agency that really gets digital, but you’ll find it here at Radar.

I can t speak highly enough about Practice s delivery on this project. A thorough scoping process and understanding of our objectives, plus great design and wonderful tech, all backed up by a supportive and considerate client service team.
Nicole Smith, Osteoporosis Australia

We passionately believe that there are many untapped ways to leverage digital solutions to improv. read more

We passionately believe that there are many untapped ways to leverage digital solutions to improve communication in the healthcare industry. Here are a range of clients that have benefited from our passion.

Privacy Policy

RADAR is committed to providing you with the best possible customer service experience. RADAR is bound by the Privacy Act 1988 (Crh), which sets out a number of principles concerning the privacy of individuals.

Collection of your personal information

There are many aspects of the site which can be viewed without providing personal information, however if you wish to access RADAR customer support features you will be required to submit personally identifiable information. This will include but may not be limited to a unique username and password, and the provision of sensitive information if you need to recover a lost password.

Sharing of your personal information

We may occasionally hire other companies to provide services on our behalf. Those companies will be permitted to obtain only the personal information they need to deliver the service. RADAR takes reasonable steps to ensure that these organisations are bound by confidentiality and privacy obligations in relation to the protection of your personal information.

Use of your personal information

For each visitor to reach the site, we expressly collect the following non-personally identifiable information, including but not limited to browser type, version and language, operating system, pages viewed while browsing the Site, page access times and referring website address. This collected information is used solely internally for the purpose of gauging visitor traffic, trends and delivering personalized content to you while you are at this Site.

From time to time, we may use customer information for new, unanticipated uses not previously disclosed in our privacy notice. If we do change our information practices and update our Privacy Policy at some time in the future, any data collected before that date will continue to be used only in accordance with the original terms of our Privacy Policy.

Operational Security and Disaster Recovery

To minimize service interruption due to hardware failure, natural disaster, or other catastrophe, Radar implements a disaster-recovery program for our data. This program includes multiple components to eliminate single points of failure, including data replication and back-up, resilient and redundant infrastructure and a continuity plan in the event of disaster.

Changes to this Privacy Policy

RADAR reserves the right to make amendments to this Privacy Policy at any time. If you have objections to the Privacy Policy, you should not access or use the Site.

Accessing Your Personal Information

You have a right to access your personal information, subject to exceptions allowed by law. If you would like to do so, please let us know. You may be required to put your request in writing for security reasons. RADAR reserves the right to charge a fee for searching for, and providing access to, your information on a per request basis.

Contacting Us

The following terms and conditions indicate RADAR’s general policy when engaging with clients, and are provided for general information only. A specific contractual agreement will be entered into with all new clients, and will cover these and other areas in more detail.


The price quoted to the client is for the work specifically agreed to only. Should the client add to the scope of work then additional charges may apply. Correspondingly, should the client scale back the scope of work a refund is not guaranteed. The conditions where a refund is not guaranteed includes when a total project discount of costs has been provided. Refunds may also only be provided if no work has commenced on an item that has been removed from the project scope, or de-scoped.

Project Delivery

The project schedules, time lines and delivery dates expressed by RADAR in any document or by any other means of communications are indicative estimates only. There may be occasions where product delivery or demonstration of completion of works does not correspond to these expressed schedules, timelines or dates. Project delivery may be delayed as a result of third party vendors’ internal delays or delays in the provision of client feedback, materials, materials compatibility or milestone sign-off.

Payment Methods

Unless otherwise agreed, payment is only accepted by direct bank deposit, credit card or cheque. If payment is made by cheque, then works corresponding to the payment will commence upon clearing of the cheque payment funds in RADAR’s account.

Payment of Balance

Invoices are only issued corresponding to pre-defined payment milestones or pre agreed terms. Payment of invoices is required for work to commence on the quoted project. We reserve the right not to launch a website or deliver final artwork for printed materials until full payment has been received.


Should the client wish to cancel the project after payment of any first deposit amount, then any initial project deposit amounts are refundable pro-rata taking into account any work to date such as estimating, scoping and planning since the date the project was approved to proceed. Should the client wish to cancel at any other point during the process they shall remain liable for the work that has taken place and shall be invoiced accordingly.

Exclusion of Liability

Except in relation to property damage (excluding loss of data), injury or death it is agreed by the client that RADAR will not be liable for any damages or loss incurred by the client including, loss of revenue, loss of opportunity and loss of profit. The client also agrees that RADAR will not be liable for any damages incurred indirectly by any third parties related to the client or the client’s business, where the third party may seek legal action or compensation of any kind from the client.

Pharmaceutical Sciences, BSc Hons #shionogi #pharma #inc

#pharmaceutical science


Pharmaceutical Sciences, BSc Hons Undergraduate

Pharmaceutical Sciences, BSc Hons

This programme has been developed as a result of the university’s close contacts with the pharmaceutical industry and prepares students for working in higher scientific grades in the industry. While this degree does not carry any exemption from Royal Pharmaceutical Society of Great Britain examinations, graduates gaining employment in the pharmaceutical industry may be able to progress to qualified person status through further professional development. Graduates are eligible for the award of Associate Membership of the Royal Society of Chemistry. The aims of the programme are:To provide students with a knowledge of the physiological and pharmacological basis of drugs action, read more

Not what you were looking for?

See more programmes

This is programme information for 2016. Thinking of starting next year?

See the 2017 programme information

See these programmes

Based on your UCAS score you should definitely call us if you are interested in this programme!

Based on your UCAS score you are unlikely to meet the requirements for this programme. Don’t worry, there are other programmes you could join this year!

This programme is now full for 2016 entry. Don’t worry, there are other programmes you could join this year!

Call us on
020 8331 9000 to discuss options.

This is a UK phone number and calls will be charged at your standard geographic rate.

Entry requirements may change during Clearing.

B208 M BSc/PharS (Extended)

Our extended degree is a 4-year programme. In the first year we teach you the baseline academic skills to excel in your degree.

Top 20 generics companies by 2014 revenue #pharmaceutical #articles

#generic drug companies


Top 20 generics companies by 2014 revenue

To most of the world, the term “generic” suggests something everyday, common or bland, but to the drug industry generic is anything but bland. It represents a high-volume, low-margin business that is certainly not for sissies.

It calls for scientific and manufacturing skills, a superb sales operation, and fortitude. It comes with risks but also has plenty of rewards. In the U.S. the largest drug market in the world, generic drugs account for 80% of the prescriptions written. According to data from the market intelligence miners at EvaluatePharma. worldwide sales of generic drugs in 2014 were $74.2 billion, up 7% for the year. Of that, the top 20 generics producers collected $61.7 billion, 83.1% of the take.

But the fact is, most of those 20 hold only a fraction of the whole. Only the top two generics companies, Teva Pharmaceuticals ($TEVA) and Novartis ($NVS), which sells generics through its Sandoz operation, hold double-digit shares, 12.2% and 11.5% respectively. Only the top 5 generics companies, which in 2014 also included Mylan ($MYL), Actavis and Sun Pharmaceutical, held a market share above 5%. To dice it another way, those top 5 had 2014 generics sales of $35.2 billion, 47.4% of the worldwide generics sales and 57% of the sales generated by the top 20. You get the picture.

Still, when you look at the tail end of the spectrum, even number 20, Japan-based Nichi-Iko Pharmaceutical, had generics sales of $1.2 billion.

The current year may be remembered for awhile, with a lot of M A germinating, some of it friendly, some not so friendly. Teva has a $40-plus-billion deal to buy essentially Actavis, the generics business of Allergan ($AGN), which has decided to trade in its generics heritage to concentrate on the branded side of the ledger. That deal will elevate Teva’s leading position so that it should be unreachable in size for some time. Meanwhile, Mylan is trying rather awkwardly to pull off a buyout of Perrigo ($PRGO), which Perrigo is working hard to avoid.

It is worth noting that there was some significant M A action in generics in 2014, like Mylan’s $5.7 billion deal to buy Abbott Laboratories’ ($ABT) generics business in developed countries and Sun Pharmaceutical’s $4 billion takeover of troubled Indian compatriot Ranbaxy Laboratories.

Other notable events in 2014 exemplify some of the challenges of the generics business. High drug prices have become the topic du jour recently, but last year a number of generics players said employees had been subpoenaed by federal prosecutors to give up information on potential collusion on pricing. Impax Laboratories ($IPXL) and Lannett both acknowledged in 2014 that employees in their operations had received DOJ subpoenas seeking info on generic drug pricing.

All of this adds up to a piece of the pharma industry that is steady and profitable, and not at all bland. Take a careful read through this report and let any of the 5 editors who contributed to it know what you think. — Eric Palmer (email | Twitter )

Book traversal links for Top 20 generics companies by 2014 revenue

Therapeutic Innovation #top #10 #pharma

#mylan pharma


Mylan Worldwide

Therapeutic Innovation

Would it surprise you to know that we bring innovation to the field of generic medicine? Or that our research and development group includes more than 2,900 scientists and regulatory experts who innovate worldwide every day?

It s true. And it s why we ve challenged ourselves to reach higher and go farther for more than 50 years.

The Science of Solutions

Today we design bioequivalent versions of brand name medicines, many of which are difficult-to-manufacture and difficult-to-formulate. We strive to create enhanced versions of medicines to differentiate our products from the pack. And we pursue innovations in oral solid dose medicines, transdermals, injectables, creams, ointments, antiretrovirals and nearly a dozen other critical areas.

Why? Because we believe every disease can have a treatment. We believe every epidemic should come to an end. Medical conditions great and small should be manageable.


From treatments for solid tumors and cancers of the blood to supportive care, Mylan helps healthcare professionals provide their patients with a wide variety of treatments for every stage of cancer survivorship. Learn more about Mylan’s commitment to oncology.


Anaphylaxis, a life-threatening allergic reaction, is a significant public health problem. When anaphylaxis occurs, every minute matters and immediate access to epinephrine and emergency medical care is crucial. We advocate for increased anaphylaxis awareness, preparedness and access to treatment. because even one anaphylactic episode without access to epinephrine is one too many.


These medicines treat HIV/AIDS. Often, treatment regimens require a patient to take three or more medicines and may include an ARV medicine that breaks down if not refrigerated. Many places hardest hit by the epidemic are in warm climates Africa and India, for instance where refrigeration can be scarce. For such regions, Mylan was able to make a heat-stable version of an ARV medicine that doesn t require refrigeration.


Our commitment to cardiovascular medicine beats strongly. Using our transdermal technology we have formulated adhesive patches that deliver medicine through the skin.


We re developing asthma and chronic obstructive pulmonary disease (COPD) treatments that use a dry-powder drug-delivery platform technology. Find out more about our other brand name respiratory products.


While we manufacture products in many formats from tablets and capsules to injectables and transdermals we also produce creams and ointments for dermatology. Our commitment to these medicines gained strength during the 1990s, when we acquired Bertek Pharmaceuticals. Today, we have several products in clinical trials awaiting approval as well as many creams, ointments, sprays and dressings .

Central Nervous System

Mylan products are the second-most dispensed in the neurologic category. These are difficult-to-manufacture and difficult-to-formulate products that treat serious diseases. Our innovation in this category has made us a leader in this area.

Resources and information to help prescribe, dispense and take medicine with confidence.


Educational materials to help empower your customers.

  • Patients

    What to know about our high quality generics.

  • Physicians

    Details about our brand name and generic medicines.

  • Health Systems Customers

    Resources that meet the specific needs of your institution.

  • BSc (Hons) Pharmaceutical Science with Optional Sandwich Placement #health #it #companies

    #pharmaceutical science


    BSc (Hons) Pharmaceutical Science with Optional Sandwich Placement/ Study Abroad BSc (Hons)

    Pharmaceutical scientists play a vital role in the development of new medicines, from discovery chemistry, through to formulation development, manufacture and clinical testing, and post marketing pharmacovigilance.

    We have developed our Pharmaceutical Science programme in collaboration with a range of local and national companies. As a direct result we have significantly increased the laboratory hours offered to our undergraduates.

    Our connections with these major pharmaceutical companies ensure this course is relevant and continues to meet the needs of today s graduates. In addition, these links will provide you with unique opportunities to gain valuable experience during your placement year and utilise the knowledge of the best visiting lecturers from the pharmaceutical industry.

    The range of modules we offer allows you to understand the fundamental underpinning sciences of chemistry, biochemistry, biology, and pharmacology before building specialist knowledge in drug design, formulation development and clinical testing, whilst equipping you with the essential skills employers want to see in their graduate employees. Our links with major pharmaceutical companies ensure this course is up to date and meeting the needs of today s graduates.

    Why choose this course?

    First year
    You will study modules introducing you to the fundamentals of pharmaceutical chemistry and analytical chemistry, biology and biochemistry, as well as a human physiology and pharmacology. You will learn to use a range of experimental techniques and analytical tools in practice as well as in theory. You will develop strong data evaluation and presentation skills.

    Second year
    You will study analytical chemistry at an advanced level, dosage form design and manufacture, methods in drug design, formulation development and a more specialist pharmacology module. This will give you the scientific knowledge, laboratory and analytical skills to undertake a work placement year in any stage of the pharmaceutical drug development pipeline with one of our overseas partners.

    Work placement/study abroad
    We strongly recommend that our students undertake a supervised work placement; recent placements have been based in government and charity-funded research institutions, healthcare companies, agrochemical, pharmaceutical and biotech companies, environmental agencies and the NHS.

    Alternatively, you can choose to spend the year studying at one of our partner universities.

    Final year
    In your final year you will spend one entire semester carrying out an independent extended research project, enabling you to develop and hone the laboratory, research and documentation skills sought by employers. You will also study modules in pharmaceutical industry practice; simulating real life industry scenarios, and the translation of laboratory science into clinical trials and marketed products, as well as being able to specialise in a core discipline including medicinal chemistry, pharmaceutical formulation development or pharmacology.

    Entry requirements.


    Please call the clearing hotline number on 0300 303 6300

    Market Research Reports, Forecasts and Industry Analysis from BCC Research #shionogi #pharma #inc

    #market research reports


    Market Research Collections from BCC Research

    This BCC Research report deals exclusively with wireless technologies employed in the personal area network (PAN) and local area network (LAN) topologies. It forecasts the market size of wireless sensors from 2015 to 2021.

    This BCC Research report analyzes and measures the market for conventional conductive polymer composites, which incorporate conductive fillers in an insulative resin to achieve a measure of conductivity. Includes forecasts through 2021.

    This BCC Research report provides a comprehensive analysis of the pharmacy automation market’s current operations and equipment, current trends and detailed patent analysis. Structure and current market size of the pharmacy automation market are outlined with forecasts through 2021.

    This BCC Research report assesses the current state-of-the-art in synthesizing QDs, identifies the current market players seeking to exploit QD behavior, evaluates actual or potential markets in terms of application, type and projected commercial market revenues. Forecast provided through 2021.

    This BCC Research report analyzes the changing global food industry and its business climate, including data relating to and discussion of the diet and food distribution systems and major factors that affect markets for food and food additives. Forecasts provided through 2021.

    This BCC Research report provides an understanding of the ballast water treatment equipment industry and the market forces that affect it. Forecasts provided from 2015 to 2020.

    This BCC Research report provides an update on the most advanced processes employed for the fabrication of thin films, nanofilms and ultrathin films. Includes forecasts through 2021.

    Semiconductor Manufacturing – August 2016

    • Important Milestone Reached in 3-D Printed Circuit Boards An Israel-based electronics printing tech firm has completed the development of a software package for integration in the company s 3-D printer. The DragonFly 2020 3-D printer, currently in development, will use proprietary inks and the integrated software to quickly create fully functioning printed circuit board (PCB) prototypes.
    • Home Users Are Catalyst for Patient Monitoring Device Market Remote patient monitoring is drawing keen interest in the market for patient monitoring devices (PMDs). According to projections by BCC Research, the PMD market will grow from nearly $16.9 billion in 2015 to almost $23.8 billion in 2020, reflecting a five-year compound annual growth rate (CAGR) of 7.1%. Last year, hospitals were the largest segment of the PMD end-user market, representing 51% of the total end-user market. But in terms of growth, home users are the fastest-growing end-user segment. The market for glucose monitoring and other devices that enable patient self-monitoring at home is expected to grow during BCC Research s forecast period.
    • In Space, No One Can Hear You Bio-Print Human Organs Two high-tech companies have teamed up to develop a 3-D bio-printer capable of manufacturing human organs and tissues in orbit. The joint effort could result in the ability to manufacture transplantable organs in space for patients on earth, and help enable long-duration human exploration of deep space.
    • The Brave New Applications of PCR Technology Technological advances are yielding different types of polymerase chain reaction (PCR) techniques. BCC Research reveals in a new analysis that the use of PCR technology continues to expand into nonconventional applications, producing solid growth in the global market. PCR allows DNA sequencing, as well as the production of millions of copies of a specific DNA sequence, within minutes. As a result, PCR technology has helped make molecular diagnosis easier and faster. It is used frequently to diagnose disease, identify bacteria and viruses, and aid forensic investigations. And, so much more.
    • Biosimilar Therapies for Rheumatoid Arthritis Win Favor of FDA Panel The race is on to get biosimilar versions of the rheumatoid arthritis (RA) treatments Humira, the world s top-selling drug, and Enbrel, also in the top five, to market. Companies are simultaneously defending their own biologic treatments and developing biosimilars. Case in point: Last month, Amgen floated on a recommendation from an FDA panel to approve its alternative to AbbVie s Humira. But the following day, Novartis Sandoz division won similar support for FDA approval of a biosimilar to Amgen s Enbrel. The landscape is changing fast, as companies both vie to protect their blockbusters and try to chip away at their competitor s market share.
    • Marketing Your Business During Major World Events – Part Two Major world events, such as national or international sporting competitions are a great time to connect with your customers and introduce or even reintroduce yourself. You can build upon a great relationship by demonstrating to your customers that your company has passion, or a sense of humor, or even just that you support the things they care about.
    • Marketing Your Business During Major World Events – Part One Some things are just better when enjoyed with other people. We are social beings, and there is both a thrill and a primal satisfaction in sharing an experience. Two examples are watching an anticipated film in a theater full of eager moviegoers, or celebrating your hometown team s victory in a packed stadium. In both cases, the energy and excitement of others fuels and heightens the emotional impact to the individual.
    • Accenture Launches Advanced Analytics Applications to Detect Fraud Advanced analytics enables all stakeholders who deal with fraud to analyze their organization s business data to gain insight into the dynamics of internal controls and identify fraudulent or suspicious transactions that heighten the risk of fraud.
    • Obama Names Smart Manufacturing Innovation Institute Winner This past June, the Obama administration highlighted America s capacity for creativity and invention by announcing that the Smart Manufacturing Leadership Coalition (SMLC) will lead the new Smart Manufacturing Innovation Institute, in partnership with the Department of Energy.

    Featured Reports

    Global Markets for Automotive Sensor Technologies

  • 3-D Scanning: Technologies and Global Markets

  • Global Markets for Catheters

  • GPhA Website #msd #pharma

    #generic drug companies



    Drug Shortages


    Patent Settlements


    Improving Lives for Less

    *New data* The 2015 Generic Drug Savings in the U.S. report shows that generic pharmaceuticals saved the U.S. health system $254 billion in 2014. For the first time, this year s report features state-by-state savings . therapy area and public program savings and more. Data compiled by the IMS Institute for Healthcare Informatics. Learn more

    Value and Quality

    The Biosimilars Council, a division of the Generic Pharmaceutical Association (GPhA), works to ensure a positive environment for patient access to biosimilar medicines.

    Click here for more information.

    2015 Annual Report

    The 2015 Annual Report is now available. GPhA furthers the industry s goal to improve the lives of consumers by providing timely access to high quality, affordable medicine. Together, we continue to drive value and quality for patients. Learn More

    Featured Items

    Recent News

    GPhA Response to September 2, 2016 Clinton Campaign Position Paper on Drug Pricing

    GPhA Statement on the Generic Drug User Fee Amendments

    Biosimilar Approval is Step Toward Improving Access, Savings for Patients and.

    GPhA Calls for Policy Changes to Enhance Pharmaceutical Competition

    Biosimilars Council: Patients Can Trust Biosimilars and Providers Can Confidently.

    Market Research Reports and Industry Analysis from JSB Market Research #contract #pharmaceutical #companies

    #market research reports


    Market Research Reports and Industry Analysis

    JSB Market Research Pvt.Ltd was formed in 2013 and the portal for quality primary market research reports was launched to dedicatedly provide quick search service to global clients with no restriction to any industry verticals.

    We favour timeliness of deliverables as one of the prime points of business in today’s competitive market research arena. For us, the process adds value to our core business. But, as a competing firm with, JSB Market Research Pvt.Ltd is equally aligned to providing quality reports to clients.

    Accelerating business prospects with our market research reports

    Partnering with JSB enhances the industry analysis and market understanding. It also updates the present business line along with foresight to new ventures and spaces.

    JSB works on user requirements and how to promote business scale with end to end user specifications. This technique makes market research report and its outcome more beneficial for the clients. Not just restricted to pre-made services or products, JSB Market Research undertakes customization of projects, where in our clients can demand market research reports as per their specification.

    Management Team – Pharma Start

    #cro pharma


    Management Team

    “We are committed to high quality deliverables and optimal patient treatment, by providing a personal investment in each project that we take on.”

    As the founder of Pharma Start, Dr. Christina Fleming provides the company’s strategic direction by leveraging her 20+ years of biopharmaceutical and Clinical Research Organization (CRO) industry experience. Dr. Fleming’s experience includes building, managing and leading Clinical Development, Medical Writing, and Pharmacovigilance Divisions at Searle (formerly Pharmacia, now Pfizer), TAP (now Takeda), Neopharm Inc, and Baxter Healthcare as well as developing the outsourcing/CRO consulting services at several CROs. This experience led her to create and develop Pharma Start into a highly successful and unique outsourcing organization. Dr. Fleming is a 2010 recipient of PharmaVoice’s Top 100 Most Inspiring People in the Life Sciences Industry award and is a member of DIA, AMWA, and RAPS. Dr. Fleming earned her Bachelor of Science (BS) in Biology at Saint Mary’s College and her Doctor of Philosophy (PhD) in Pharmacology from the University of Illinois at Chicago.

    ” ‘Winging It’ is not a project plan; communication, foresight, and flexibility create project success.”

    Marcy Komocsar has over 15 years of pharmaceutical, device, and biotechnology experience. Marcy’s career includes positions of increased responsibility in the safety and medical writing departments at Searle (Pharmacia, now Pfizer), Allos Therapeutics, Takeda (TAP) Pharmaceuticals, and Baxter Healthcare. In 2006, Marcy transitioned to the outsourcing and CRO space, directing Medical Writing groups. At Pharma Start, Marcy leads a team of writers, editors, and document specialists who have finalized >25 NDAs/505(b)(2)s, and hundreds of CSRs, peer-reviewed journal articles, manuscripts, abstracts, and conference posters. Marcy’s team of professionals has a high rate of FDA approval and dossier acceptance. Marcy is a graduate of Indiana University School of Nursing and a current member of the Drug Information Association (DIA), Women in Bio, the National Association of Professional Women, and the American Medical Writers Association (AMWA).

    “Constant learning is a must in this global quality and regulatory landscape.”

    Thomas McGrady has 25+ years of experience in Quality and Regulatory in the pharmaceutical, biotechnology, and medical device industries. Tom has served in QA/RA leadership roles at the plant, divisional, and corporate levels at companies such as Astellas US, Baxter Healthcare, and completed project work for companies such as Abbott Laboratories, Cardinal Health, and Pharmacia. He is highly experienced in GxP regulations, technology, and system validation and possesses expertise in the development and management of global quality systems. Tom earned his Bachelor of Science (BS) in Microbiology from Purdue University and his Master of Business Administration (MBA) in Finance from the University of Illinois (Chicago).

    “I enjoy bridging the gap between science and medicine. “

    Dr. Paulson has over 25 years experience in the pharmaceutical industry and contributed to submissions of numerous sNDAs, NDAs and INDs for both large and small molecules including Celebrex and HUMIRA. Her work has resulted in numerous publications and several patents. Dr. Paulson was most recently Director of Clinical Pharmacology and Pharmacometrics at Abbott Laboratories. Prior to Abbott, she held positions in Clinical Pharmacology and Drug Metabolism at NeoPharm and Searle/Pharmacia. She is an adjunct professor in the Department of Pharmacology and Biological Chemistry at Northwestern University Feinberg School of Medicine

    What is Health IT (health information technology)? Definition from #pharmaceutical #industry #statistics

    #health it companies


    Health IT (health information technology)

    Health IT (health information technology) is the area of IT involving the design, development, creation, use and maintenance of information systems for the healthcare industry. Automated and interoperable healthcare information systems are expected to improve medical care, lower costs, increase efficiency, reduce error and improve patient satisfaction, while also optimizing reimbursement for ambulatory and inpatient healthcare providers.

    Download this free guide

    Free Guide: Wearables Raise Healthcare Data Security Questions

    Is the information collected by Fitbits and Apple Watches covered by HIPAA regulations? Only sometimes. Find out more about what’s covered – and what isn’t – when it comes to wearable devices and data so you can avoid the risks.

    By submitting your email address, you agree to receive emails regarding relevant topic offers from TechTarget and its partners. You can withdraw your consent at any time. Contact TechTarget at 275 Grove Street, Newton, MA.

    You also agree that your personal information may be transferred and processed in the United States, and that you have read and agree to the Terms of Use and the Privacy Policy .

    Types of health information technology

    The electronic health record (EHR ) is the central component of the health IT infrastructure. An EHR or electronic medical record is a person’s official, digital health record and is shared among multiple healthcare providers and agencies. Other key elements of the health IT infrastructure are the personal health record (PHR ), which is a person’s self-maintained health record, and the health information exchange (HIE ), a health data clearinghouse or a group of healthcare organizations that enter into an interoperability pact and agree to share data between their various health IT systems.

    Implementations of EHR systems have increased dramatically in the past few years since the inception of the HITECH Act in 2009, which introduced the EHR meaningful use program. Physicians and hospitals that prove their use of government-certified EHR systems meets meaningful use criteria — created and overseen by the Centers for Medicare Medicaid Services and the Office of the National Coordinator for Health IT (ONC) — are eligible to receive incentive payments. Meaningful use is changing to a new value-based reimbursement system under a law passed by Congress in 2015 called MACRA, the Medicare Access and CHIP (Children’s Health Insurance Plan) Reauthorization Act. However, ONC continues to certify approved health IT technology used under federal reimbursement programs.

    Picture archiving and communication systems (PACS) and vendor neutral archives (VNAs) are two widely used types of health IT that help healthcare professionals store and manage patients’ medical images. In the past, radiology departments have been the primary repositories of medical images, but PACS and VNAs are integrating radiology into the main hospital workflow, and other specialties such as cardiology and neurology have also become large-scale producers of clinical images. In some instances, VNAs have been installed as a way to merge imaging data stored in separate departments’ image banks in a multi-facility healthcare system.

    Management of health IT systems

    Due to the threat of patient data breaches. widespread use of mobile health devices and telemedicine technologies, and updates to health IT-related incentive programs and regulations, providers that adopt health IT systems sometimes replace or upgrade their systems.

    Healthcare organizations and their business associates, such as third-party billing companies, that handle protected health information (PHI) are subject to the Health Insurance Portability and Accountability Act (HIPAA) Privacy Rule. created and enforced by the U.S. Department of Health and Human Services. The rule mandates that patients have full access to their PHI and protects the privacy of their information by limiting access to it by other parties. A healthcare provider that experiences a breach of PHI can be fined by the HHS Office for Civil Rights .

    Benefits of health information technology

    While some critics say EHRs have led to reduced physician productivity and produced cumbersome federal regulations, there is broad consensus on the benefits of health IT. These benefits include the ability to use data analytics and big data to effectively manage population health programs and reduce the incidence of expensive chronic health conditions, the use of cognitive computing and analytics to perform precision medicine tailored to individual patients, the ability to share health data among academic researchers to develop new medical therapies and drugs, and the rights of patients to obtain and use their own health data and collaborate in their own care with clinicians.

    Health IT challenges

    Some major challenges persist in health IT. Chief among them are obstacles to interoperability, including a lack of commonly agreed on health data interchange standards, although the health IT standard-developing organization HL7 International (Health Level Seven) has developed and promulgated several popular standards, most recently FHIR (Fast Health Interoperability Resources). Also, federal officials and patient advocates have identified as a pervasive problem the alleged practice of information blocking by some vendors and providers in an attempt to stymie the ability to share health data in their systems. Other ongoing concerns in health IT are the usability of EHR systems, with some physicians and other clinicians complaining about poorly designed user interfaces, and cybersecurity vulnerabilities that have made health systems susceptible to frequent cyberattacks on health data networks by criminals, foreign state actors and insiders.

    This was last updated in June 2016

    Next Steps

    Continue Reading About Health IT (health information technology)

    Pharmaceutical research and development #cipla

    #pharmaceutical research companies


    Pharmaceutical research and development

    Pharmaceutical research has great importance for Finland

    Clinical trials boast a long tradition in Finland and have great societal importance for the country. Continued research operations also guarantee the future competence of the Finnish scientific community. However, the number of new trials is decreasing in a worrisome manner.

    In Finland, pharmaceutical companies of various sizes, research companies specialised in pharmaceutical development, and academic researchers perform medical research and clinical trials that are also noteworthy by international standards.

    The competition between various countries for the venue of the clinical trials is increasingly tough. Finland’s future success calls for

    • a good research environment
    • smooth process of evaluation by the authorities
    • a positive research attitude shown by the people
    • cost-efficiency – Finland is an expensive country but we will do well if we act in a smart way

    It is also important that the healthcare system provides possibilities for research. Research requires time from the doctors who also need to have passion for research and a sufficient number of suitable patients.

    Safeguarding future research is imperative

    We need to safeguard the future conditions of research because it is vital for Finland in many ways:

    • Research employs competent people in hospitals, universities and companies.
    • Doctors familiarise themselves with new therapies.
    • Patients get new therapy options.
    • Finnish research competence grows at universities, research institutes, healthcare and companies.
    • Finnish research community remains in tune with international developments.

    Healthcare resources are curtailed while work pressures increase. Researchers have fewer opportunities to participate in clinical trials. Critical evaluation of published research calls for personal hands-on experience in doing research.

    Investigating doctors also have the possibility to learn about new pharmacotherapies before they are introduced to the daily work. Investigators know best who will benefit from novel medicines.

    We need a change: besides practical patient work, a research career should also be attractive to doctors in training. This calls for long-term funding and time to dedicate to research.

    Smooth permit processes

    Smooth and rapid permit processes in healthcare constitute an integral element of research competitiveness and efficiency.

    Collaborating with the national Sub-Committee on Medical Research Ethics TUKIJA, Pharma Industry Finland PIF has produced useful tools and documents for the parties assigning pharmaceutical research projects. Moreover, with the Association of Finnish Local and Regional Authorities, we have drafted a template contract to facilitate negotiations.

    CPR Pharma Services #pharma #blog

    #cro pharma


    Welcome to CPR Pharma Services

    CPR Pharma Services ( CPR ) is a full-service CRO with an international reputation for delivering superior clinical trial results in Australia, New Zealand and Asia through our Fast2PhaseOne and Access2Asia services.

    As the premier provider of early phase clinical trial services in the Asia-Pacific region for over a decade, we have leveraged our extensive experience to now offer an expanded range of services. CPR can assist you to:

    • Get your trial underway quickly and cost effectively via our Fast2PhaseOne service
    • Confidently navigate entry into the Asian market via our Access2Asia service
    • Provide bioanalytical support in the Asia-Pacific via our FDA-inspected laboratory in Australia
    • Access the Australian Government s attractive R D Tax Incentive through our strategic partnership with one of Australia s leading taxation experts
    • Get your trial back on track through our Recovery Centre .

    Please peruse our website to learn more about CPR and our team of experts. or contact us directly to discuss your specific requirements.

    Get it right first time with CPR the experts in early phase clinical research.

    FDA Audit – Complex peptide no challenge for CPR scientists

    With the in-life component of a clinical trial completed, a large multinational pharmaceutical company approached CPR to help develop a peptide assay to complete the bioanalysis to report data before an FDA deadline closed.

    New Ligand Binding Assay Service – CPR expands APAC offering with large molecule analytical service

    CPR s new laboratory, in Adelaide, Australia now offers best practice ligand binding assay services for biomarkers, monoclonal antibodies, biosimilars and biologics in early and late phase clinical trials the first APAC based laboratory to offer such an extensive range of GLP services.

    Pharma Agency R1 #cipla

    #pharma agency


    humane products

    Lactic acid bacteria

    The harmony of intestinal microflora may be disrupted by many factors. Most common of these are stress, antibiotic treatment, chronic constipation, ingestion of contaminated food, unsuitable eating habits, irradiation, and weather and climatic change /travel/. To restore intestinal balance bacteria must be provided that are favourable for the body that exhibit anti-infection effects, stimulate immunity, reduce the risk of developing allergy, and impact positively on the course of inflammations. Use of probiotics is suitable in all age categories. The advantage of probiotic cultures are practically their zero side or undesirable effects, even when the recommended dose is accidentally exceeded.


    veterinary products

    Where bacteria are of help

    In my veterinary practice I use probiotic preparations for three patient groups. The first group are animals suffering from diarrhoea caused by dietetic errors (food poisoning) such as sudden change of fodder, supplementary feeding with various fodder supplements, lactose intolerance. The second group includes patients on long-term medication because of chronic infections. The third group I have found to be helped greatly with probiotics are animals after gastrointestinal tract surgery (e.g. gastrotomy, enterotomy, or states after large intestine constipation caused by skeletal/bony coprolites).


    Pharma CRM: CRM designed for pharma partnering #catalent #pharma

    #pharma crm


    Pharma CRM

    Pharma CRM meghan Fleming 2016-05-13T12:18:00+00:00

    Partnering is critical for pharma companies, which is why they need a pharma crm for partnering. To find the right partners, pharma companies must evaluate thousands of opportunities, resulting in an enormous amount of data to manage. This information comes from a multitude of sources such as partnering conferences, information databases, email, colleagues, online portals and more. On top of all that, pharma companies are spread all over the world, making it even more difficult share and keep up-to-date information for their global teams. To overcome these challenges, pharma companies need one central place to manage their partnering information – they need a CRM designed for pharma partnering.

    The #1 Pharma CRM for Partnering

    Inova provides the CRM designed for pharma companies. The solution is made up of Partneringplace, Deals and Alliances. Partneringplace connects to BIO and EBD partnering events, tracking your company’s meetings and the related contacts, assets, notes, documents and emails, from one conference to another, all year-round. The Deals and Alliances modules go further, managing the partnering process from scouting to due diligence and licensing to alliance management. Enhanced reporting enables users to quickly report on their activities and share the information with their colleagues.

    Inova’s solutions are designed for partnering in the life sciences, which means that they are ready to use right out-of-the-box and leverage industry best practices. Inova’s workflows were created to work the way you do, making it the bestpharma CRM .

    Integrated into the Life Sciences

    Inova is dedicated to the life sciences industry. We’ve worked with our pharma and biotech clients for 15 years to develop solutions tailor-made for their partnering needs. To put all your partnering information in one place, our solutions connect to key industry players such as BIO and EBD conferences, Thomson Cortellis and Citeline. Today, Inova is the #1 Pharma CRM for partnering, and our roadmap is driven by the desire to continue helping our life science clients find the right partners faster.

    CDRD-Canada – s national drug development – commercialization engine #juventus #pharma

    #drug research companies


    On June 3rd, CDRD hosted our global partners including the US National Institutes of Health (NIH), the European Infrastructure for Translational Medicine (EATRIS), Therapeutic Innovation Australia and MRC Technology (UK).

    On May 26th, CDRD hosted a partnership appreciation lunch and open house. Thank you to everyone for your ongoing support!

    Quark Venture has made a significant seed investment in Sitka Biopharma – a critical value-creating event that will enable Sitka to advance their lead compound for the treatment of bladder cancer into clinical trials.

    In total, over one-third of all the life science companies included in the 2016 Ready to Rocket and Emerging Rocket Life Sciences lists have received support, mentorship and/or expertise from CDRD.

    Health sciences researchers, entrepreneurs, and companies alike have the opportunity to collaborate with CDRD and thereby access its full suite of expertise, infrastructure, and broad partnerships and networks.

    Introducing Zucara Therapeutics Inc. a new start-up company created by MaRS Innovation and CDRD.

    Zucara is developing a novel drug therapy to reduce the severity and frequency of hypoglycemic (low blood sugar) episodes in people with diabetes.


    • Over 1,100 early-stage technologies evaluated for commercial potential
    • Over 200 projects on 134 distinct technologies
    • 56 technologies advanced toward commercialization and/or commercialized
    • 7 spin-off companies launched
    • 14 technologies out-licensed

    What is CDRD?

    Headquartered in Vancouver, British Columbia, The Centre for Drug Research and Development (CDRD) is Canada’s national drug development and commercialization engine.

    We work in partnership with academia, industry, government and foundations, to provide the specialized expertise and infrastructure to identify and de-risk promising discoveries generated by health-related research, and transform them into commercially viable investment opportunities for the private sector – and ultimately into innovative new therapies for patients.

    In doing so, CDRD is actively growing our national health sciences industry into a wholly-optimized generator of economic prosperity for the country.

    Since 2008, Canada’s Networks of Centres of Excellence Program has recognized CDRD as a Centre of Excellence for Commercialization and Research (CECR).

    Latest from the Blog

    API (Active Pharmaceutical Ingredient) #surya #pharma

    #api pharma


    What is API (Active Pharmaceutical Ingredient)?

    Updated May 27, 2016

    The Active Pharmaceutical Ingredient (API) is the part of any drug that is active. Some drugs, such as combination therapies, have multiple active ingredients to treat different diseases. While production of APIs has traditionally been done by the pharmaceutical companies themselves in their home countries, in recent years many corporations have opted to send manufacturing overseas to cut costs. This has caused significant changes to how these drugs are regulated, with more rigorous guidelines and inspections put into place.

    Components of Medications

    All drugs are made up of two core components: the API, which is the central ingredient, and the excipient, the substance inside the drug that helps deliver the medication to your system. Excipients are inactive substances, such as mineral oil, and not chemically active.

    For instance, if you have a headache, acetaminophen is the active ingredient, and the liquid in the capsule is the excipient.

    Strength of APIs

    Manufacturers use certain standards to determine how strong the API is in each drug. However, the standard can vary widely from one brand to another. One brand might use one test, another a different one.

    Top API Manufacturers

    The leading manufacturer of APIs is TEVA Pharmaceuticals. With over 300 API products, they have the industry s largest portfolio. Another leading manufacturer is Dr. Reddy s, with more than 60 APIs in use today.

    Where are APIs Made?

    While many pharmaceutical companies are located in the United States and England, most API manufacturers are overseas.

    The largest are located in Asia, particularly in India and China. More and more companies are turning to outsourcing to API manufacturers like Dr. Reddy s to cut costs on expensive equipment, employees and infrastructure.

    Notably, AstraZeneca Pharmaceuticals used to operate several manufacturing centers in the United States.

    Now, just 15% of their APIs are created in the U.S. and there are plans to end that small percentage and outsource all manufacturing overseas.


    The quality of APIs has a significant effect on the efficacy and safety of medication. Poorly manufactured or compromised APIs have been connected to serious issues, such as illnesses and even death.

    Even in the case of outsourcing, APIs are subject to stringent regulations and oversight from the country they are shipped to. For example, any APIs produced overseas for use in drugs produced in America still goes through inspection by the U.S. Food Drug Administration .

    As evidenced by the creation of APIs, the pharmaceutical industry is rapidly changing. Companies no longer handle every step of the drug-making process, from creating the API to building the capsule. In order to cut down on expenses and increase profits, companies have begun outsourcing the creation of APIs to foreign manufacturers based in Asia. While this has helped their bottom line, there is continued concern about the quality of these APIs produced overseas.

    In response, governing bodies responsible for patient safety, such as the FDA, have instituted intense screenings to ensure medication quality and prevent defects. Violating any of these established standards can result in fines or very expensive recalls for the pharmaceutical companies behind these manufacturers.

    AstraZeneca – Research-Based BioPharmaceutical Company #pharma #manufacturing #jobs

    #drug research companies


    AstraZeneca live at ERS 2016

    Meet Chris Rhodes, a renowned leader in the field of diabetes and obesity research

    I grew up in an artistic musical family, which instilled in me very early on the essence of creativity. Science requires original thinking, and cultivating and using that creativity is fundamental to innovation and momentous discovery .

    AstraZeneca’s ambitions for personalised healthcare go far beyond treating cancer

    At AstraZeneca, personalised healthcare is about matching medicines to the patients most likely to benefit from them. The approach involves a detailed understanding of the biology of a disease, identifying biomarkers and developing tests, known as companion diagnostics, which doctors can use to identify who is most likely to respond to treatment with a targeted therapy.

    New study published in ‘Cancer Cell’ furthers understanding role of CXCR2 in pancreatic cancer

    Scientists from AstraZeneca’s Oncology Innovative Medicines Unit, in collaboration with Dr. Jen Morton and Professor Owen Sansom of the Beatson Institute for Cancer Research in Glasgow, have shown how an experimental drug breaks down pancreatic cancers defences, allowing immune cells to attack the tumour. The new study, published in Cancer Cell. discovered that a protein called CXCR2 acts as a guard for the tumour, controlling how the immune system responds to pancreatic cancer.

    Clinical trial data unveil a driver of FGFR inhibitor response in gastric cancer – collaborative study published in the journal Cancer Discovery

    Scientists from AstraZeneca’s Oncology Innovative Medicines Unit, the Institute of Cancer Research, London and the Royal Marsden Foundation Trust, recently published the results of a clinical biomarker study in solid tumours. The publication defines a potential driver for clinical responses to fibroblast growth factor receptor inhibitors in gastric cancers.

    You are now leaving

    You have selected a link that will take you to a site maintained by a third party who is solely responsible for its contents.

    AstraZeneca provides this link as a service to website visitors. AstraZeneca is not responsible for the privacy policy of any third party websites. We encourage you to read the privacy policy of every website you visit.

    Click ‘cancel’ to return to AstraZeneca’s site or ‘continue’ to proceed.

    Important notice for users

    You are about to access AstraZeneca historic archive material. Any reference in these archives to AstraZeneca products or their uses may not reflect current medical knowledge and should not be used as a source of information on the present product label, efficacy data or safety data. Please refer to your approved national product label (SmPC) for current product information.

    I have read this warning and will not be using any of the contained product information for clinical purposes.

    Pharma Recruitment Agency in UK

    #pharma agency


    Job Search

    Latest Vacancies

    Our Awards

    What People Say About Us

    I found CHASE to be excellent to deal with. Real people who really understand Pharma.

    I found CHASE to be excellent to deal with. Real people who really understand Pharma, with excellent industry relationships, and who really listen to what you’re looking for in your next role.

    This allowed me to have genuine insight into different companies, and evaluate the pros and cons of different opportunities, to understand which were really worth pursuing.

    Terry, Marketing Manager

    Janice, Health Services Manager

    I was pleased to find a Company with a personal interest in the individuals they would be working with. Your friendly and professional manner made the decision to join CHASE an easy choice.

    I was pleased to find a Company with a personal interest in the individuals they would be working with. Your friendly and professional manner made the decision to join CHASE an easy choice.

    I was particularly impressed with your individual approach to myself and understanding my particular needs and requirements for a new job. You have made looking for a position hassle free, and when the job came in you seemed to hand pick it for me.

    I would recommend CHASE to any of my colleagues looking to join a quality company.

    Janice, Health Services Manager

    I just wanted to write you a quick note to say how grateful I am for the support I have had from CHASE throughout the duration of my contract.

    I just wanted to write you a quick note to say how grateful I am formuch easier than the company for whom I am working the support I have had from CHASE throughout the duration of my contract.

    I have been so impressed with how supportive you have been, how helpful when I have had any problems and how you’ve gone the extra mile for me.

    All the office staff I have dealt with have been really helpful, and I would gladly recommend this agency to other colleagues.

    I have found CHASE a pleasure to work with. All the office staff I have dealt with have been really helpful, and I would gladly recommend this agency to other colleagues.

    I have found the Head Office support to be excellent with a team who are committed to ensuring the field are well informed and made to feel valued.

    I have found the Head Office support to be excellent with a team who are committed to ensuring the field are well informed and made to feel valued.

    Reliable, professional and extremely polite in the office.

    I have found CHASE to be a very professional organisation from the moment I first contacted my recruiter Kelly.

    I have found CHASE to be a very professional organisation from the moment I first contacted my recruiter Kelly.

    She was excellent at keeping me up to date with opportunities as they arose.

    Now that I am an employee of CHASE I have found the administration and processes so easy and clear to follow.

    The administration staff are always on hand to help and I love the way they even remind us to send our figures in on time!

    Having spoken to some of my colleagues who work for different contract companies, I feel very relieved that I am with CHASE. I have heard horror stories with other companies of expenses going missing etc

    Don, Galen, Sales Director

    Recently having re-established a working partnership with CHASE I am delighted at the service level achieved and the candidates for Healthcare Managers referred to me.

    Recently having re established a working partnership with CHASE I am delighted at the service level achieved and the candidates for Healthcare Managers referred to me.

    Careful listening to my profile brief for candidates. rigorous pre-screening by CHASE consultants has made the recruitment process very efficient.

    I have recruited 4 HSMs from the 5 presented to me just outstanding!

    Don, Galen, Sales Director

    Michael, NSM, Tillotts

    I have worked both for CHASE and with CHASE for many years so I have worn both an employee and client hat.

    I have worked both for CHASE and with CHASE for many years so I have worn both an employee and client hat.

    Regardless of the role I can say with total honesty that their professionalism shines through everything they do. Be it the speed and quality of back office support as an employee or the way they go the extra mile to find me the highest quality candidates for vacancies I find the processes are faultless. I particularly value the fact that they face to face interview every potential candidate for roles as that enables me to trust their recommendations and not waste my time when recruiting staff.

    Michael, NSM, Tillotts

    Connecting People With

    About us – Member Companies #pharmaceutical #healthcare #companies

    #pharmaceutical research companies


    About us Member Companies

    The vfa, the Association of Research-Based Pharmaceutical Companies (vfa), is the trade organization of research-based pharmaceutical companies in Germany. 45 leading research-based pharmaceutical companies are organized in the vfa. Together with their more than 100 subsidiaries and affiliated companies, they employ nearly 80,000 people in Germany.

    The vfa members represent more than two-thirds of the entire German pharmaceutical market. The vfa member companies are among the leading research-based pharmaceutical companies worldwide. They guarantee therapeutic progress in pharmaceuticals and ensure high-quality pharmaceutical therapy.

    In Germany more than 18,000 of their employees work in the field of research and development of pharmaceuticals. Here, the research-based pharmaceutical companies invest EUR 5.2 billion per year in pharmaceutical research. The Association of Research-based Pharmaceutical Companies represents a German high-tech industry that is competitive in the international markets.

    The Pharmaceutical Industry in Germany

    Germany: The Perfect Location for Research, Production and Sales – a publication by GERMANY TRADE INVEST and vfa
    Brochure Download

    Epic pharma #top #20 #pharmaceutical #companies

    #epic pharma



    EPIC PHARMA began operations in mid-2008 by purchasing the Sandoz facility located in Laurelton, NY.

    We are dedicated to developing and manufacturing generic prescription drugs in a variety of therapeutic categories in tablet, capsule and powder forms.

    In addition to internal drug development and manufacture,

    we also offer contract manufacturing services with an emphasis on quality, customer satisfaction and low cost.

    We have a proven track record as we are the largest contract manufacturer in the United States for a large pharmaceutical company.

    Epic Pharma’s continues to diversify it’s portfolio by adding new products in powder, capsule and tablet forms.

    For more information, contact customer service at 1-888-EPIC-RX

    EPIC operates a 110,000 square foot facility with approximately 200 employees. Our facility is a fully functional FDA approved manufacturing facility. We utilize state of the art machinery, technology, and techniques to bring our customers high quality products on time every time. We have the ability to manufacture a diverse portfolio of products including CII – CV controlled products.

    Pharmaceutical Distribution Software from IBS #pharmaceutical #sales #representative

    #pharma software


    Pharmaceutical Distribution Software

    Industry Trends

    The pharmaceutical market is in constant change, and the demand to continuously adapt expansive supporting systems is extreme. As companies grow through mergers, acquisitions and alliances, it becomes increasingly important to have a system that is easy to maintain in multiple facilities, locations, platforms, regions and languages.

    Pharmaceutical distribution places a heavy burden on the operational and logistics resources of any company. Industry-specific regulations and institutional requirements, forecasting, procurement, customer service, picking, dispatch and special treatment of physical inventory can all place a burden on logistical decisions. Add to that low margins, high customer service expectations, a constant fight against counterfeit medicines and global competitive pressures, and the margin for error is negligible.

    No wonder government monitoring and regulations have increased. As borders open up and generics increasingly flood in, consumers are beginning to buy direct, blurring industry lines between wholesale and retail distribution and straining the supply chain from the manufacturer down to basic provider levels.

    How do you manage this unwieldy and heavily monitored supply chain? How do you ensure rapid delivery of perishable and critical medicines while balancing compliance, customer satisfaction and profitability issues? Is your system up to the intense data and integration requirements it takes to be a world-class provider in this highly fragmented and ever-changing landscape?

    IBS can help. Our expertise in managing pharmaceutical distribution operations is long-standing and proven, providing the latest thinking in logistics for an industry that never stops moving.

    Business Drivers

    IBS specializes in pharmaceutical business software, matching a staggering amount of pharmaceutical wholesalers’ specific requirements out-of-the-box. It’s a distribution solution for fast implementation and integration worldwide.

    Using our deep, proven knowledge of the industry, we can help you tailor a customized solution specifically for your business that drives value, meets your organization where you are today and prepares you for where you want to go tomorrow.

        • Sales: Our integrated order entry system ties warehouse, logistics and invoicing to unique customer orders placed online, at a store or through your call center for accurate, traceable, controlled delivery and payment.
        • Procurement: Automate and optimize procurement processes across the supply network, based on accurate inventory forecasts to meet various order sizes, types, minimums and seasonal demands.
        • Warehouse management: Streamline warehouse activities, from goods reception and quarantines, to pick verifications, controlled substances and combined transport, using multiple shipping systems and paperless automation technologies.
        • Financials and accounting: Make any financial process easy-to-manage and totally transparent, including handling multiple simultaneous currencies.
        • Compliance: Rest assured having a defensible system that automates, captures and complies with your specific distribution requirements and regulations, including our unique, global “counterfeit compliance solution.”
        • Lot Tracking/Recall: Ensure reporting and data integrity, especially vital for FEFO (first end date first out) products, to assist with regulatory compliance and recall ability.
        • Complex Rebates and Chargebacks: Automatically track details for accurate sales management and accounting.

    IBS pharmaceutical clients include Galexis, Sigma, Panarello, Associated Pharmacies Inc, Marzam, Alloga, Drogueria Betances, Oriola, uniPHARM Wholesale Drugs, MWI Veterinary Supply, TopRX, Strategic Pharmaceutical Solutions, North Carolina Mutual Drug, Metro Medical, Sandvik Medical, Mediq, LLC Wholesale, Sunset Pharmaceuticals, and ICS/AmerisourceBergen to name a few.

    Pharmaceutical – Medical Sales Recruitment Agencies #top #drug #companies

    #pharma agency


    Scientific Pharmaceutical Recruitment Agency

    Industry Specialization

    Spectrum Staffing Services is a top pharmaceutical recruitment agency, serving clients and candidates in NY, NJ, NC, and across the country. Our pharmaceutical sales recruiters and medical sales recruiters specialize in placing qualified candidates into rewarding career opportunities with top employers. Spectrum provides the following industries with Contract, Contract-to-Hire, Direct Hire and RPO staffing services:

    • Consulting and Engineering Design Industry
    • Pharmaceutical Industry
    • Medical Device Industry
    • Bio/Medical Industry
    • Scientific/Laboratory Industry
    • Research and Development
    • Life Sciences Industry
    Scientific Pharmaceutical Jobs We Place

    Spectrum places scientific and business professionals in many of the following careers:

    • Regulatory Affairs
    • Quality Control
    • Scientists
    • Drug Safety
    • Chemists
    • Quality Assurance
    • Packaging
    • Product Development
    • Packaging Design

    If you re a candidate looking for scientific or pharmaceutical job opportunities, or an employer seeking out talented professionals, the staffing experts at Spectrum will get you on the right track. Contact us today to learn more about our pharma recruitment services.

    Here are 10 of the fastest growing health IT companies, according to Inc #surya #pharma

    #health it companies


    Here are 10 of the fastest growing health IT companies, according to Inc.

    The interest in using health IT tools as a way to improve healthcare delivery and efficiency has produced many rapidly growing healthcare companies, many of which can trace their origins within one or two years of Obamacare s passage. These companies have reached a stage of their development to accelerate growth and that has coincided with a readiness by healthcare providers and payers to adopt or ramp up their technology.

    With a nod to the top healthcare company on Inc s 5,000 Fastest Growing Companies, molecular diagnostic companies with smartphone-enabled technology have also become more attractive as investment and acquisition targets.

    Overall, healthcare companies on the list collectively generated $21.8 billion in revenue. more than any other sector. There were more startups on the list this year than global and franchise businesses put together. So how did healthcare do. I held the count under 500, to keep it manageable.

    Crescendo Bioscience was the fastest growing healthcare company. The 12-year-old molecular diagnostic company in San Francisco, which Myriad Genetics acquired last year. did an impressive sprint to its ranking of 7th this year compared with 67th last year. The company represents a convergence of biotech and digital health. Its Vectra DA Test is used to detect 12 biomarkers in the blood to confirm a diagnosis and to indicate the severity level of rheumatoid arthritis. The test gives a score between 1 and 100 — the lower the number the lower the disease activity. Doctors can also use the test to determine whether there is joint erosion, bone erosion or cartilage breakdown. Its MyRA app, helps RA patients identify parts of the body where they experience pain and make notes and indicate how they feel day to day. The app also helps users generate a visual summary report tracking their data so patients and their doctors can see how they’re doing between visits.

    The HCI Group . a health IT consultancy has been around since 2009, doing installations for electronic health records, validation, testing, optimization and ongoing support, according to Inc. Its revenue shot up to $34.5 million last year compared with $259,420 in 2010. In an interview with HIStalk earlier this year, Chief Strategy Officer Cythia Petrone-Hudock said the company works with clients to identify what their needs are and to develop creative solutions that reduce the cost of healthcare and improve their ability to increase the quality of healthcare, particularly in the realm of electronic medical records. We were established to meet the system implementation needs of healthcare organizations, but we promote cost-effective solutions.

    Medhok is a Software as a Service company to improve clinical outcomes and quality measures. It links reimbursement to better outcomes for health plans, accountable care organizations, patient-centered medical homes, and other groups. It generated $17 million in revenue for 2013, according to Inc. compared with $185,000 in 2010. It has added 92 jobs in the past three years.

    Nordic is a health IT consultation company that provides services to healthcare facilities that use fellow Madison, Wisconsin electronic medical record producer Epic. It ranked 46 after having a huge revenue growth spurt from $1.4 million in 2010 to $81.4 million three years later.

    Connexion Point is a Salt Lake City company that develops programs to help health plans and providers communicate with members about health care choices and benefits. It ranked 86 on the list but was the fastest growing company in Utah. Since the Affordable Care Act was passed it has grown from four to 1,252 staff.

    LaunchPoint is a healthcare analytics business that s also the parent company of Discovery Health Partners and Ajilitee. It ranked 100 on the list with $12.8 million in revenue. In a statement. CEO Terrance Ryan said its payer clients are interested in improving their claim payment integrity, how they manage information, and analytic insight needs that have been amplified with healthcare reform.

    MobileHelp s medical alert monitoring tools include an event notification and online tracking platform for families and caregivers. It ranked 111 on the list, with $18.6 million in revenue last year, compared with a little more than $548,000 in 2010.

    hCentive s technology supports the state and federal health insurance exchanges and marketplace. It has added about 430 staff in the past three years to support exchanges as people seek to enroll in plans to comply with ACA. It has also boosted revenue to $26.4 million, earning it a rank of 117 on the list. In a statement, Sanjay Singh, the CEO, said, We see continued growth for our products as more states and private insurers look to simplify and streamline their offerings.

    CareCloud, an EHR software and medical billing software provider, ranked 127. It achieved $10.4 million in revenue last year and has added 193 jobs in the past three years. It developed an eye-catching user interface that centralizes patient information with data like account balance, clinical summary and notes, among other things. It also has a set of patient engagement tools. In an interview with HIStalk. CEO Albert Santalo pointed out that the first employee he hired was a designer.

    CoverMyMeds automates drug prior authorizations for medications and health plans. It ranked 280 after boosting revenue to $18.6 million last year from $1 million in 2010.

    Global pharma sales to reach $1 #pharma #info

    #pharmaceutical market size


    Global pharma sales to reach $1.3 trillion

    The 2015 CMR Pharmaceutical R D Factbook reveals a surge in global sales – reaching a milestone of $1 trillion in 2014 – and forecasts continued growth with the expectation of sales reaching $1.3 trillion by 2018.

    The pharmaceutical market is not in an “Era of Scarcity” as some analysts describe the Pharma R D environment post-2005. Industry data challenges negative perceptions and demonstrates the pharma industry’s continued commitment to creating and employing innovative solutions to tackle its largest hurdles.

    Key highlights from the 2015 Factbook include:

    Diversification is increasing New Molecular Entities (NME) launches

    2014 saw the highest amount in 17 years with 46 NME launches. One third of 2014 launches were for rare indications, mainly within Anti-cancer. More than 65 percent were specialty drugs for the treatment of Anti-cancer, Hepatitis C Virus and HIV.

    Anti-cancer development continues to attract the greatest amount of investment across all therapeutic areas. The majority of recent launches have received orphan drugs status from regulatory authorities.

    Failing fast and cheaply

    An improved ability to “fail fast and cheaply” has enabled Phase III pipeline volumes to grow at a steady rate.

    Our Factbook has been built in collaboration with the leading global pharmaceutical companies since 2003. The analysis draws on data from proprietary, primary sources, competitive intelligence, and public sources covering key trends across the landscape, including:

    • R D pipeline volume
    • Success rates
    • Cycle times
    • Regional comparisons
    • Therapeutic areas
    • Generics

    Thomson Reuters feedback

    Jobs ucb Group – at ucb Group Careers – Experteer #hikma #pharma

    #ucb pharma careers


    Jobs at ucb Group

    289 openings matching your search Jobs in ucb Group”

    Raleigh, NC – Director, Patient Safety Scientist
    Director, Patient Safety Scientist UCB on LinkedIn Featured Careers Pharmaceutical Medical Careers Scientific Careers Sales and Marketing Corporate Careers Sign in Our Company Search by Keyword Search by Location Director, Patient Safety Scientist Apply now » Apply now Start apply with LinkedIn Start apply with.

    Atlanta, GA – Associate Director, Romosozumab Global / US Marketing
    Requisition ID 41026 – Posted 06/24/2016 – United States – Georgia – Atlanta – Marketing We all share one big ambition. What’s yours? Everyone who works at UCB holds the same ambition – to transform the lives of people living with severe diseases. Of course we have other associated ambitions too – including a.

    Denver, CO – Regional Associate Director, Immunology Field Medical – West
    Requisition ID 40841 – Posted 06/16/2016 – United States – Field Based – Field Based – Medical Affairs We all share one big ambition. What’s yours? Everyone who works at UCB holds the same ambition – to transform the lives of people living with severe diseases. Of course we have other associated ambitions too -.

    Raleigh, NC – Associate Director of Partnership Management- Business Excellence
    Requisition ID 40882 – Posted 06/17/2016 – United States – North Carolina – Raleigh – Drug Safety & Pharmacovigilance We all share one big ambition. What’s yours? Everyone who works at UCB holds the same ambition – to transform the lives of people living with severe diseases. Of course we have other associated.

    Seattle, WA – Immunology Medical Science Liaison – Pacific Northwest
    Requisition ID 3413 – Posted 11/20/2014 – United States – Washington – Seattle – Medical Affairs At UCB, we strive to be the patient centric biopharmaceutical leader. We are small enough for each member of our team to feel that their contribution counts and large enough to ensure that our combined efforts have an.

    Atlanta, GA – National Partnership Lead – Southeast
    Requisition ID 36804 – Posted 02/10/2016 – United States – Georgia – Atlanta – Sales We all share one big ambition. What’s yours? Everyone who works at UCB holds the same ambition – to transform the lives of people living with severe diseases. Of course we have other associated ambitions too – including a desire to.

    New York City, NY – National Partnership Lead – Northeast
    Requisition ID 36805 – Posted 02/10/2016 – United States – New York – New York – Sales We all share one big ambition. What’s yours? Everyone who works at UCB holds the same ambition – to transform the lives of people living with severe diseases. Of course we have other associated ambitions too – including a desire.

    Atlanta, GA – Global Marketing Lead, axSpA
    Requisition ID 37641 – Posted 02/24/2016 – United States – Georgia – Atlanta – Marketing We all share one big ambition. What’s yours? Everyone who works at UCB holds the same ambition – to transform the lives of people living with severe diseases. Of course we have other associated ambitions too – including a.

    Atlanta, GA – Global Marketing Lead, axSpA
    Requisition ID 37641 – Posted 02/24/2016 – United States – Georgia – Atlanta – Marketing We all share one big ambition. What’s yours? Everyone who works at UCB holds the same ambition – to transform the lives of people living with severe diseases. Of course we have other associated ambitions too – including a.

    Tampa, FL – Executive Account Manager (Tampa)
    Requisition ID 37402 – Posted 02/20/2016 – United States – Florida – Tampa – Sales Could you sell a lifeline? Are you passionate about selling, but want to make a difference to people’s lives? UCB is a solutions company treating not just diseases but individual people, enabling them to lead a fuller life. Our.

    100 Companies by Revenue Headliners #robinson #pharma

    #health it companies


    100 Companies by Revenue Headliners

    | Reprints

    While every company in the HCI 100 is making a strong mark in the field of healthcare IT, some stand out further than others. To be up for inclusion in our Headliners section, companies must first make that made the top 40 in our ranking. After that, we looked at vendors that have, for example, taken ownership in a particular niche, grabbed the reigns of a leading-edge technology, or been active in the M A realm by snapping up competitors.

    Selecting these companies was not easy. As there are so many worthy companies, competition was fierce, and editors fought for their favorites in closed-door meetings. But when all was said and done, we feel as if our 2007 Headliners represent some of the most outstanding leaders in the field – companies that don’t just do what their clients tell them, but suggest to their clients what to do.

    We trust you’ll enjoy our 2007 Headliners profiles. – the Editors

    Companies (Rank ) in the Healthcare Informatics 100 List

    Notification to Pharmaceutical Companies: Acceptance of third-party data integrity audit for Cetero studies conducted from

    #pharmaceutical companies in houston tx


    Notification to Pharmaceutical Companies: Acceptance of third-party data integrity audit for Cetero studies conducted from March 1, 2008 to August 31, 2009

    On July 26, 2011 FDA notified pharmaceutical companies that bioanalytical studies conducted at Cetero between April 2005 and June 2010 in support of marketing applications may need to be repeated or confirmed. FDA took this action as a result of two inspections of Cetero s bioanalytical facility in Houston, Texas conducted in 2010, as well as the company s own investigation and third party audit. The inspections and audit identified significant instances of misconduct and violations of federal regulations, including falsification of documents and manipulation of samples.

    Sponsors are responsible for addressing the concerns that FDA raised in the July 26, 2011 Untitled Letter and how those concerns relate to their individual studies.

    FDA is notifying pharmaceutical companies of the current actions that need to be taken pertaining to certain time frames.

    • April 1, 2005, to February 29, 2008. Studies that were previously submitted as part of an approved or pending application, or studies that will be submitted as part of a new application, will need complete reanalysis (if adequate stability data exist) or repeat of the study.
    • March 1, 2008, to August 31, 2009. The Agency will accept studies for submission and review if the sponsor performs an independent third-party data integrity audit using the Bioanalytical Electronic Raw Data Audit Plan (provided by FDA). Further, studies that were previously submitted as part of an approved or pending application will also need verification of data integrity by an independent third-party audit.
    • September 1, 2009, to June 15, 2010. The Agency will accept studies for submission and review without reanalysis, repeating, or further audit by Cetero or a third party.

    With respect to the bioanalytical studies conducted between March 2008 and August 2009, the following are requirements for the use of third-party audits:

    • Sponsors may hire independent third-party auditors, or they may use the independent third-party auditor hired by Cetero.
    • Third-party auditors are independent of the sponsor and Cetero and are qualified by training and experience to conduct laboratory and vendor audits, including review of data collected by the Analyst . AB SCIEX software.
    • Independent third-party auditors must use the Bioanalytical Electronic Raw Data Audit Plan (provided by FDA).
    • For all third-party audits, Cetero will permit auditors access to all raw and electronic data, data systems, and any paper records pertinent to the audited studies.
    • The audit will cover 100% of the portion of each study conducted at Cetero and will be conducted following the official audit protocol agreed to and maintained by FDA.
    • Along with an audit report, third-party auditors will provide a statement certifying that the audit was independently conducted.
    • The sponsor will submit full audit reports of all audited studies to the FDA, regardless of the outcome of the audit.
    • Cetero will immediately communicate to sponsors and to FDA any missing data or manipulation concerns identified during Cetero s own internal investigations.

    When studies with associated third-party audits are submitted for review, FDA will evaluate and make decisions concerning acceptability for each submission.

    Sponsors who plan to conduct data integrity audits for studies conducted from March 1, 2008, to August 31, 2009 should contact the relevant FDA review division in the Office of Generic Drugs or the Office of New Drugs and obtain the Bioanalytical Electronic Raw Data Audit Plan prior to initiating an audit.

    Related Information

    Pharmaceutical Packaging and Healthcare Packaging #schwartz #pharma

    #pharmaceutical packaging companies



    Firstan Quality Packaging is one of the leading pharmaceutical packaging manufacturers in the UK. Firstan provides outstanding customer service from the outset and we also offer a full design service if required.

    We are specialists in providing pharmaceutical packaging solutions for folding box board cartons. Our award winning in house CAD design team produce innovative pharmaceutical carton packaging designs from folding cartons through to pillow boxes and unique bespoke designs for blisters, syringes, bottles and dispensers.

    Our pharma packaging division is focussed on delivering the highest quality pharmaceutical packaging in the shortest time possible. At the heart of the Firstan pharmaceutical packaging operations is an extensive Quality Management system in order to ensure every job is dispatched in full and in perfect condition.

    To guarantee product security, Firstan offers the latest anti-counterfeiting design measures. We can provide security printing and tamper evident features when requested. Firstan are also specialists in braille application.

    To ensure smooth delivery of your pharma packaging project you will have a dedicated key account manager to liaise with at every point. Firstan have invested in sophisticated machinery ensuring your printed pharmaceutical cartons are of the highest standards and are produced as efficiently as possible.


    With well over 15 years experience in braille origination and application, Firstan have developed extensive tried and tested methods for braille embossing.


    Braille embossing is a vital component of today’s pharmaceutical packaging requirements, as part of a wider commitment to aiding those with visual disabilities.

    From October 2008 it became a requirement of Pharmaceutical packaging designs to contain information for the visually impaired. Braille is always applied as a separate layer on digital artwork, using the industry standard braille font Marburg Medium and is created in a specific layer that differentiates it from the carton design.

    For proofing and verification the braille is repeated and translated to standard type outside of the artwork bleed area.

    Just-in-time (JIT) manufacturing, also known as just-in-time production is a methodology aimed primarily at reducing flow times within production as well as response times from suppliers and to customers.

    Firstan work according to JIT manufacturing processes to ensure your order is delivered on time in full with maximum efficiency and minimum waste.


    If you would like more information regarding our Pharmaceutical Healthcare packaging solutions or are interested in using this service, we would be delighted to hear from you.

    Firstan offers tamper evident packaging solutions which can be built into the design of the carton.

    Packaging tampering can potentially render products unsafe, dangerous or in some cases even fatal. Firstan’s tamper evident system – M-lock provides a clear indication that tampering has occurred and can protect your customers and brands from potentially harmful interference.

    Brand protection is a vital component of today’s Pharmaceutical and Healthcare markets. Firstan are very aware of the need for companies to protect their ip, identities and market share. Firstan work closely with Pharmaceutical and Healthcare companies to devise an array of both overt and covert anti-counterfeiting measures, giving our customers the best brand protection available on the market.

    Firstan use overt and covert security methods to ensure that products are robustly protected from counterfeiting. All of these methods are deployed ‘in-line’ with no significant increase to ‘make-ready’ or production times. Integration of these methods starts right from the design stage, when Firstan’s experienced, skilled team are able to advise on the best practical methods specific to a customer’s requirements.

    Another aspect of brand protection offered by Firstan is in store security. Firstans CAD team build in innovative Tamper Evident features that offer excellent protection without compromising pack strength, shelf presence or customer experience.

    Firstan have invested in ‘in-line’ application of Sensomatic, Checkpoint and various other store security tags. These are incorporated deep into the design of Pharmaceutical and Healthcare cartons, making their removal impossible without first breaking open the Tamper Evident features. While the anti-counterfeit and security methods employed are tried and tested, Firstan constantly stay alert to the latest developments in the market. This is to ensure Firstan are always able to offer customers the very best.

    Firstan have invested in ‘in-line’ application of Sensomatic, Checkpoint and various other store security tags.

    The Packaging Centre,
    Cardinal Way,
    PE29 2XN

  • +44 (0) 1480 418418
  • +44 (0) 1480 418400
  • Firstan Quality Packaging is recognised as the UK’s leading independent Pharmaceutical and Food packaging manufacturers offering design and printed cartons worldwide.

    Firstan produce over 500 million cartons annually at our ‘next generation’ facility in Cambridgeshire. Primarily serving the Pharmaceutical, Healthcare, Cosmetics and Food retail industries.

  • Novum Pharmaceutical Research Services #market #research #reports

    #pharmaceutical companies in houston tx


    Trust 40-plus years of industry experience. Novum is a full-service CRO with numerous FDA approvals in ANDA and NDA submissions. We conduct more than 250 studies a year across multiple therapeutic areas and have developed long-standing relationships with a wide range of global sponsors who rely on our Early Phase Research and Clinical Trial Management expertise. Read More »

    Novum provides a full spectrum of services in managing multicenter Clinical Endpoint Studies and in conducting Early Phase Studies in our Novum facilities, from protocol design to final report. We offer reliable, turnkey solutions for your drug development program and ensure that every service we perform is designed to provide timely output of the high-quality data your study demands.

    Latest News

    Novum’s Scientific Leadership to be Featured Presenters at the EUFEPS/AAPS Second International Conference

    Novum senior team members will be featured presenters at the EUFEPS/AAPS Second International Conference. Read More »

    Novum To Attend DIA 2016 Annual Conference

    Novum will be making its rounds at the upcoming DIA 2016 Annual Conference. Read More »

    Novum To Attend Canada Talks Pharma 2016

    Novum senior team members will be present at Canada Talks Pharma 2016. Read More »

    Epic Pharma LLC Company Information #pharmaceutical #sales

    #epic pharma


    Epic Pharma LLC

    Humanwell Healthcare Group and PuraCap Pharmaceutical agreed to acquire Epic Pharma in March 2016.

    Drugs Associated with Epic Pharma LLC (aquired by PuraCap Pharmaceutical)

    Epic Pharma LLC (aquired by PuraCap Pharmaceutical) manufactures, markets and/or distributes more than 19 drugs in the United States. Medications listed here may also be marketed under different names in different countries. Non-US country and region specific information is not available on this page.

    Average User Rating

    Latest Drug Information Updates

    • Troxyca ER Troxyca ER (oxycodone hydrochloride and naltrexone hydrochloride) is an extended-release, abuse-deterrent.
    • Adlyxin Adlyxin (lixisenatide) is a once-daily prandial glucagon-like peptide-1 (GLP-1) receptor agonist indicated.
    • Xiidra Xiidra (lifitegrast) is a lymphocyte function-associated antigen-1 (LFA-1) antagonist indicated for the.
    • Epclusa Epclusa (sofosbuvir and velpatasvir) is a nucleotide analog polymerase inhibitor and pan-genotypic NS5A.
    • Byvalson Byvalson (nebivolol and valsartan) is a beta adrenergic blocker and an angiotensin II receptor blocker (ARB).
    • Zinbryta Zinbryta (daclizumab) is an interleukin-2 receptor blocking antibody indicated for the treatment of relapsing.


    Was this page helpful? Mobile Apps

    The easiest way to lookup drug information, identify pills, check interactions and set up your own personal medication records. Available for Android and iOS devices.



    Terms Privacy


    Subscribe to receive email notifications whenever new articles are published. provides accurate and independent information on more than 24,000 prescription drugs, over-the-counter medicines and natural products. This material is provided for educational purposes only and is not intended for medical advice, diagnosis or treatment. Data sources include Micromedex (updated Aug 9th, 2016), Cerner Multum (updated Aug 1st, 2016), Wolters Kluwer (updated Aug 8th, 2016) and others. To view content sources and attributions, please refer to our editorial policy .

    We comply with the HONcode standard for trustworthy health information – verify here

    Copyright 2000-2016 All rights reserved.

    Pharmaceutical Packaging Companies – Medical Components #orchid #pharma

    #pharmaceutical packaging companies


    Pharmaceutical Markets

    Working with customers within the pharmaceutical markets, including Bespak, Astra Zeneca and GSK for more than 30 years, IAC has the experience, the knowledge and the insight to ensure it provides the best pharmaceutical packaging products possible, with consistency and quality at the heart of the process.

    IAC currently supplies a significant percentage of the worldwide demand for anodised aluminium ferrules and the company is rightly proud of the relationships it has developed with the global pharmaceutical markets.

    All IAC operations are validated in accordance with the important guidelines governing the pharmaceutical industry.

    Experienced IAC employees can devise a brand new protocol in line with customer’s requirements to ensure validation and compliance is entrenched in all of its production processes from raw material to finished product. Whether dealing with pharmaceutical packaging companies or medical packaging companies, high standards and rigorous quality control is guaranteed.

    A – Z Pharmaceutical, Inc #jobs #in #pharmaceutical #industry

    #drug manufacturer


    A Z Pharmaceutical, Inc.

    Latest Drug Information Updates

    • Troxyca ER Troxyca ER (oxycodone hydrochloride and naltrexone hydrochloride) is an extended-release, abuse-deterrent.
    • Adlyxin Adlyxin (lixisenatide) is a once-daily prandial glucagon-like peptide-1 (GLP-1) receptor agonist indicated.
    • Xiidra Xiidra (lifitegrast) is a lymphocyte function-associated antigen-1 (LFA-1) antagonist indicated for the.
    • Epclusa Epclusa (sofosbuvir and velpatasvir) is a nucleotide analog polymerase inhibitor and pan-genotypic NS5A.
    • Byvalson Byvalson (nebivolol and valsartan) is a beta adrenergic blocker and an angiotensin II receptor blocker (ARB).
    • Zinbryta Zinbryta (daclizumab) is an interleukin-2 receptor blocking antibody indicated for the treatment of relapsing.


    Was this page helpful? Mobile Apps

    The easiest way to lookup drug information, identify pills, check interactions and set up your own personal medication records. Available for Android and iOS devices.



    Terms Privacy


    Subscribe to receive email notifications whenever new articles are published. provides accurate and independent information on more than 24,000 prescription drugs, over-the-counter medicines and natural products. This material is provided for educational purposes only and is not intended for medical advice, diagnosis or treatment. Data sources include Micromedex (updated Aug 9th, 2016), Cerner Multum (updated Aug 1st, 2016), Wolters Kluwer (updated Aug 8th, 2016) and others. To view content sources and attributions, please refer to our editorial policy .

    We comply with the HONcode standard for trustworthy health information – verify here

    Copyright 2000-2016 All rights reserved.

    Pharma Consulting Group #ims #pharma

    #pharma consulting


    Where there is a will, there is a way

    Let’s face it, we’re in a heavily regulated and rather complex industry. There are literally hundreds of ways of doing things, some of which might take you to the next level and some of which whom may send you back to square one. What we offer is the experience. In the business of clinical trials, knowledge is power. That’s why we’ve established a highly competent team that can provide you with the expertise and practical know-how you need to stay one step ahead of the competition.

    Our CORE values set us apart from other CROs, they are the heart of our company and influence everything we do. C ommitment, O wnership, R esponsibility and E xcellence.

    Our success depends on your satisfaction with our services, from providing the best advice for your needs to submitting the highest quality clinical data. Our CORE company principles lie at the heart of everything we do, and strengthen the lasting and trusting relationships that we value with all of our partners.

    It’s important that all of our staff take these values into their personal belief system, to guide their professional behaviour with resulting benefits not only for themselves, but also their colleagues and, of course, our partners.

    Combining a passion for people, extensive expertise and the tenacity to innovate, PCG is a place where CRO knowledge meets technological prowess.

    Pharma Consulting Group was founded in 2003 by two Swedes, Sverre Bengtsson and Henrik Blombergsson, who were frustrated with the industry’s inefficient workflows. They developed the internationally renowned Viedoc™ EDC system, which has now been used in over 900 trials in 64 countries worldwide.

    Since then, the company has evolved into its two separate entities, PCG Clinical Services and PCG Solutions. which focus respectively on delivering excellence in services and technology for clinical studies.

    We provide a wide range of clinical services, from Advisory and Project Management, through to Clinical Operations, EDC, Biometrics, Data Management, Medical Writing, QA, Auditing and Validation. These capabilities are all supported by our commitment to excellence. You can rely on us to deliver high quality and effective studies, on time.

    Get the details of our history and growth as a company over more than a decade.


    PCG was founded

    It all started with Henrik Blombergsson and Sverre Bengtsson, two experienced CRO professionals that grew tired of the outdated workflows of their industry. They took matters in their own hands by founding PCG, or Pharma Consulting Group, in their hometown of Uppsala, Sweden in 2003.


    First client

    After receiving the first assignments from local biotech companies, the PCG team quickly realised that present EDC systems were outdated, resulting in time-consuming processes that shouldn’t be necessary with 21st century technology. There simply wasn’t a good enough solution on the market, so they decided to design their own, and Viedoc was born. Shortly thereafter, Claude Marcus became the first client to ever try the system. He’s been with the firm since.


    From one to seven

    The firm quickly grew to seven employees and became the first company in the world to get approved following the new EU Clinical Trials Directive. Assignments within biometrics were accompanied by the first clinical operations and PCG started exploring the opportunities for international establishment.


    50 studies 500 active sites

    The offices were becoming too small as the company grew to 14 employees, with 50 studies and 500 active sites.


    First international assignments

    Word of PCG’s revolutionary Viedoc platform was travelling fast. PCG gained its first client outside Sweden and started looking at international expansion to Japan.


    Trips to Japan

    The company grew to 25 employees and began its international division with emphasis on Japan.


    PCG earns a Gazelle

    PCG was awarded with the “Gazelle” award by Dagens Industri (Sweden’s largest business paper), celebrating the company’s stable growth over the previous four years. In addition, a global contract was signed with Pfizer and PGC was formally established in Japan.


    Goodbye, old office!

    PCG moved into its new, 1000 sqm headquarters in Uppsala, Sweden.


    50 employees, 50 countries

    With the release of the highly anticipated Viedoc 4 just around the corner, the future was looking more promising than ever. With 50 employees and activity in over 50 countries, PCG welcomed CEO Karin Meyer to lead global operations. As the company was at its most exciting phase, the system development and consultancy divisions were incorporated individually to enhance focus and stimulate growth.


    New CEO

    The number of employees exceeded 60 and Andy Babington took over as the new CEO.


    650 studies 9.000 sites

    As part of PCG’s continued progression and ambitious plans for expansion, a new company website was released. PCG’s number of studies and sites exceeded 650 and 9000 respectively. The rest is history in the making…

    We believe in teamwork, and we are proud to have an excellent management team with key expertise in all required fields of the clinical trial process.

    Small cap pharma stocks: Latest News – Videos, Photos about small cap pharma stocks #pharma

    #small pharma companies



    10 small cap stocks which caught the fancy of fund managers

    Despite rich valuations, fund managers have kept buying these shares with the hope that they will outperform in the long run.

    4 Aug, 2016, 12.30AM IST

    China stocks close lower as regulatory clampdown knocks small caps

    The CSI300 index of the largest listed companies in Shanghai and Shenzhen.

    29 Jul, 2016, 11.58AM IST

    Seven stocks to look at from small-cap universe

    It has been observed that investing in companies with improving financials and low price-earn.

    16 Jun, 2016, 05.13AM IST

    Stocks in news: Bharti Airtel, Sun Pharma

    The Indian market is expected to open higher tracking positive trend seen in other Asian markets.

    18 Aug, 2016, 08.59AM IST

    Rally takes promoters of small-cap companies past the $1 billion mark

    The average stock return of these five companies has been almost seven times higher than the BSE Small Cap index over the past two years.

    16 Aug, 2016, 11.30AM IST

    All about stocks: SBI and Sun Pharma

    After closing on the highs, markets are expected to open and perform better in the coming week. Watch this video to know the stocks that are expected to give good returns and prove to be safe bet for retail investors.

    13 Aug, 2016, 09.19AM IST

    When Rakesh Jhunjhunwala took stock of his investment in Aurobindo Pharma

    In terms of opportunity, we do not see more than three-four players getting into that. So that is the level of opportunity which exists.

    24 Aug, 2016, 10.36AM IST

    Don’t see sugar prices coming down with cap being put on stock holding: Abinash Verma, ISMA

    Abinash Verma said that government’s restriction would affect only 50-60 sugar mills and not the whole industry.

    2 Sep, 2016, 09.57AM IST

    Personal finance corner: Small cap rally to stay?

    In a chat with ET Now, Dhirender Kumar of Value Research talks about the small cap rally and how long will it be staying.

    1 Jul, 2016, 03.12PM IST

    Stocks to buy: Jain Irrigation, PNB, Reliance Cap

    ET Now spoke to various experts and here’s what they have to recommend for today’s trade.

    28 Jul, 2016, 09.11AM IST

    Stocks to buy: Grasim, Dishman Pharma, Jindal Steel

    ET Now spoke to various experts and here’s what they have to recommend for today’s trade.

    2 Aug, 2016, 08.40AM IST

    Stocks to buy: Reliance Cap, United spirits

    In a chat with ET Now, experts recommends stocks for the day’s trade for the investors.

    26 Jul, 2016, 08.51AM IST

    What’s in store on D-Street: Bank stocks likely to gain, IT & pharma may correct

    Traders should take calculated risk as now if market finds hurdle then sector and stocks churning cannot be ruled out, suggest experts on Dalal Street.

    29 Aug, 2016, 08.26AM IST

    Experts re-rate pharma stocks post weak Q1 show

    After the first-quarter earnings, the once bullish analysts are re-rating stocks of Dr Reddy s, Lupin and Cipla. We tell you why.

    17 Aug, 2016, 08.17AM IST

    ​Double-digit topline growth in Q1, but m-caps down by one-third! Are these stocks good buys?

    Data available with corporate database Capitaline showed these stocks belong to pharma, textiles and IT packs and also include a few credit rating agencies.

    19 Aug, 2016, 01.29PM IST

    #LeanIn: Maternity Bill passed in RS, now women to get 6 months off

    While India was rooting for PV Sindhu, Andhra Pradesh and Telangana were googling her caste

    The wait is over: iPhone 7 is coming soon

    Centre returns bill for 400 per cent hike in Delhi MLA salaries

    Price war: Idea, Vodafone and Bharti Airtel to slash tariffs to compete with Reliance Jio

    Can football help you build your portfolio?

    ‘No chance’ of returning to the family business, says Onida Group’s Sasha Mirchandani

    Best 13-inch laptops of the year

    How to permanently erase data from an Android device

    An IAS officer got a call from PM Narendra Modi at 10 PM and this is what happened next

    Smartphones which are compatiable with Reliance Jio

    Digvijay Singh terms Kashmir ‘India-occupied Kashmir’

    Reliance Jio data plan tariffs: All you want to know

    Cyclical mutual funds: Running the relay of business cycles profitably

    I spent my first salary on candies: Sunny Leone

    5 smartphones likely to launch this week

    US immigration debacle over, SRK takes selfies with fans at son’s film school

    Air India Express turns profitable for the first time


    Drug company R – D: Nowhere near $1 billion #dusa #pharma

    #drug research companies


    Drug company R D argument for half a century, but the specific source of the $1 billion claim is a 2003 study published in the Journal of Health Economics by economists Joseph DiMasi of Tufts, Ronald W. Hansen of the University of Rochester, and Henry Grabowski of Duke. I will henceforth refer to this team as the Tufts Center group, because they were working out of the (drug-company-funded ) Tufts Center for the Study of Drug Development. The Tufts Center group “obtained from a survey of 10 pharmaceutical firms” the research and development costs of 68 randomly chosen new drugs and calculated an average cost of $802 million in 2000 dollars. That comes to $1 billion in 2011 dollars based on the general inflation rate since 2000 (28 percent). One billion dollars for every little orange prescription bottle in your medicine cabinet! And according to PhRMA, even that is way too low! As of 2006, its calculation of the drug-development average had already risen to $1.32 billion. That means costs specific to drug development increased by 64 percent between 2000 and 2006. Medical inflation typically outpaces general inflation, but PhRMA’s calculation puts its rate of cost increase at more than twice the rate for medical inflation during that period (26 percent). If Pharma’s alleged inflation rate hasn’t slackened since 2006, then the drug-development average should be now approaching $2 billion. But let’s not go there. We’ll stick to Big Pharma’s official last-stated estimate of $1.32 billion.

    The new study, by sociologist Donald W. Light of the University of Medicine and Dentistry of New Jersey and economist Rebecca Warburton of the University of Victoria, and published in the journal BioSocieties. builds on some excellent previous research by journalist and health care blogger Merrill Goozner, author of The $800 Million Pill . and the consumer advocate Jamie Love. Light and Warburton begin by pointing out that drug companies submitted their R D data to the Tufts Center group on a confidential basis and that these numbers are therefore unverifiable. Light and Warburton find it a little fishy that only 10 of the 24 invited firms chose to participate, given “the centrality of the issue and the prominence of the Center” within the industry. “The sample,” they suggest, “could be skewed” toward companies or drugs “with higher R D costs.” Light and Warburton also observe that if the Tufts Center group made any effort of its own to verify the information it received from the drug companies, the group makes no mention of it in the study.

    The first research phase involved in developing a new drug is basic (as opposed to applied) research. Very little of this type of research is funded by drug companies; 84 percent is funded by the government, and private universities provide additional, unspecified funding. The Tufts Center group assumed that drug companies spent, on average, $121 million on basic research to create a new drug, but Light and Warburton find that hard to square with their estimate that industry devotes only 1.2 percent of sales to all their basic research. Add in a few additional considerations and Big Pharma would have us believe basic research costs end up constituting more than one-third of the Tufts Center’s $802 million estimate. That’s way too much, Light and Warburton say.

    Another problem Light and Warburton have with the Tufts Center group is that they didn’t subtract from their R D calculations pharmaceutical firms’ tax breaks. Research and development costs, they point out, are not depreciated over time like other investments; rather, they’re excluded entirely from taxable profits. This tax break lowers net costs by 39 percent. Add in other tax breaks and that cuts the Tufts Center group’s R D estimate in half.

    Now take that figure and cut it in half again. Light and Warburton say, because half the Tufts Center group’s estimate was the “cost of capital,” i.e. revenue foregone by not taking the money spent on R D and investing it in securities instead. But R D is a cost of doing business, Light and Warburton point out; if you don’t want to spend money on it, then you don’t want to be a drug company. And who says that investing in securities always increases your capital? Sometimes the market goes down. Many of us learned that the hard way in 2008.

    There are other problems. The Tufts Center group’s per-subject calculation of how much clinical trials cost was six times that of a National Institutes of Health study. Its calculation of how much time it takes to conduct clinical trials and have them reviewed by the Food and Drug Administration—7.5 years—is twice as long as Light and Warburton’s calculation, which is less than four years. The Tufts Center group’s use of the average (mean) cost rather than the median cost, Light and Warburton argue, is also misleading, because R D costs for different drug products vary widely, and a very few expensive drugs will skew the mean. That appears to have happened in this case, because the Tuft Center group’s median was only 74 percent of the mean.

    When Light and Warburton correct for all these flaws—well, all the ones that can be quantified—they end up with an average cost of bringing a drug to market that’s $59 million and a median cost that’s $43 million. In 2011 dollars, that’s a $75 million average and a $55 million median.

    So the drug companies’ $1.32 billion estimate was off, according to Light and Warburton, by only $1.265 billion. * Let’s call it a rounding error.

    Correction, March 7, 2011: This article originally and incorrectly stated that the drug companies’ estimate was off by $977 million. (Return to the corrected sentence.)

    An easier way to understand the pharma industry – Market Realist #pharma #technology

    #pharmaceutical industry research


    An easier way to understand the pharma industry

    The main goal of the pharmaceutical industry is to provide drugs that prevent infections, maintain health, and cure diseases. This industry directly affects the global population, so a number of international regulatory bodies monitor things like drug safety, patents, quality, and pricing. Here are some of those regulatory entities:

    • World Health Organization (or WHO)
    • US Food and Drug Administration (or FDA)
    • Medicines and Healthcare Products Regulatory Agency (or MHRA)

    The pharmaceutical industry has made a great deal of progress over the last decade due to a research-oriented approach that has improved technologies, developed infrastructures, and increased research in the field of bioscience. Thanks to biotechnology, various formulations have been developed to cure or stop the growth of several major infections, including HIV and certain types of cancer.

    The global pharmaceutical industry was worth an estimated $1 trillion in 2014. In 2013, global pharmaceutical markets generated revenues of $980.1 billion. That year, North America (the US and Canada) contributed 41% of sales, while Europe contributed 27.4%.

    Publicly traded companies and ETFs

    In the drug manufacturing category, the major publicly traded companies include Johnson Johnson, Novartis AG (NVS ), Pfizer Inc. (PFE ), Merck, Sanofi, and GlaxoSmithKline.

    Gilead Sciences Inc. Amgen Inc. (AMGN ), Celgene Corporation (CELG ), Biogen Idec Inc. and Regeneron Pharmaceuticals Inc. are the major publicly traded biotechnology companies.

    Pharmaceutical ETFs include the PowerShares Dynamic Pharmaceuticals ETF (PJP ), the SPDR S P Pharmaceuticals ETF, the iShares US Pharmaceuticals ETF, the iShares NASDAQ Biotechnology ETF, and the VanEck Vectors Pharmaceutical ETF.

    Irish Pharmacy News #pharma #contract #manufacturing

    #pharmacy news


    Welcome to IPN Communications

    Welcome to IPN Communications Ltd. an Irish based publishing company specialising in the Pharmacy sector of Ireland.

    Armed with the premier, most exciting pharmacy trade magazine in the country Irish Pharmacy News (IPN), the recently launched Hospital Pharmacy News (HPN), the yearly Irish Pharmacy Awards, the Pride in Product Awards and CPD we are constantly innovating and bringing you the best opportunity to understand how to improve your business.

    Quick Links

    Contact Us

      Office 36 Clifton House
      Lower Fitzwilliam Street
      Dublin 2

    Recent News

    A few months removed from the 2016 Iris
    Wed – 10 Aug

  • Apply now to be considered for the four
    Tue – 21 Jun

  • The IPN Pharmacy Representative of the
    Wed – 04 May

    Subscription List

    Oh no. This form doesn’t exist. Head back to the manage forms page and select a different form.

  • Humanwell and PuraCap to acquire Epic Pharma for $550m – Pharmaceutical Technology #archimedes #pharma

    #epic pharma


    Humanwell and PuraCap to acquire Epic Pharma for $550m

    Humanwell Healthcare Group and PuraCap Pharmaceutical have agreed to acquire US-based Epic Pharma in a deal valued at $550m.

    With this investment, Humanwell and PuraCap will expand their presence in the US generics market and existing commercial and manufacturing capabilities.

    The deal includes Epic’s generic product portfolio which includes tablets, two-piece capsules and powder dosage form products, as well as a future product portfolio that will include a series of controlled drug substances.

    Epic’s portfolio consists of 15 marketed generic products and a pipeline of 37 products.

    The acquisition will also bring Epic’s 110,000ft² GMP manufacturing facility in Laurelton, New York, to the companies.

    Humanwell Healthcare chairman Richard Wang said: This acquisition continues to broaden our global investments consistent with our strategy for the creation of a truly global pharmaceutical company for Humanwell Healthcare Group.

    Nearly 215 employees from Epic will join Humanwell and PuraCap’s US operations team.

    The PuraCap US footprint continues to expand our tablet, softgel, two-piece capsules, cream and powder product portfolio.

    PuraCap CEO Dahai Guo said: In addition to strong and growing OTC and branded business units in the US, this acquisition along with our recent acquisition of Blu Pharmaceutical and Blu Carib firmly establishes Humanwell and PuraCap in the US Generic Rx Pharmaceutical segment.

    The PuraCap US footprint continues to expand our tablet, softgel, two-piece capsules, cream and powder product portfolio.

    Subject to certain regulatory and shareholders’ approval, the acquisition is expected to be completed in the second quarter of this year.

    Humanwell Healthcare currently invests, develops and manages healthcare companies.

    PuraCap Pharmaceutical works in the areas of prescription brands and prescription generics, as well as OTC and private label brands.

    Image: The acquisition of Epic Pharma includes a FDA and DEA inspected GMP manufacturing facility. Photo: courtesy of PRNewsFoto / PuraCap Pharmaceutical.

    Related Content

    Pharma Software for Distribution & Wholesale Billing #vifor #pharma

    #pharma software


    Pharma Software

    Software Demo

    • Multi Rate, Price List, & Discount
    • Cash / Credit / Split Invoice & Challan
    • Sales Return & Replacement on Sale Bill
    • Party Wise Rate, Discount and Scheme
    • Salesman / Route / Area Wise Bills & Reports
    • Indication for Loss, Min, Max, New / Old Rate & Expiry
    • Negative Stock Billing Facility
    • Self-Designed Price List (Set Formula in Price List)
    • Sales Return on Same / Separate Bill & Its Adjustment
    • Back Date Stock Position at the Time of Billing
    • Switch Over from Bill to Bill Anywhere
    • Godown Wise Billing & Stock Position
    • Bill Import / Export & Message on Bill
    • Auto Calculation of Levies & no Chance of Manual Mistake
    • Display last four Deals at the Time of Billing
    • View O/s Stock, Ledger. Last Deal of Sale & Purchase Returns, Receipt Payment Bill Modification at the Time of Billing
    • Counter Sale Entry Provision
    • Party History Dashboard on Party Selection
    • Provision to Load Item from Other Bill
    • Display Last 4 Deals at the Time of Purchase to Cross Check Rate Deal, Disc Tax & Cost
    • Purchase Planning & Purchase Order Management
    • Supplier Wise Various Outstanding Reports & Remainder
    • Pending DR / CR & Replacement Notes
    • Auto Barcode / Label Printing from Purchase Bill
    • Fix Sales Rates & Deals at the Time of Purchase
    • Online Shortage Management
    • Purchase Costing Comparison
    • 1000’s of Purchase Reports & Analysis
    • Online / Softcopy Purchase
    • Items Wise Double Percentages Discounts
    • Item Wise Double Volume Discounts
    • Four Different Discounts on Complete Bill
    • Party Wise Discounts & Schemes Pre-Fixing
    • Data Wise Schemes, Quantity Based Rate & Discounts
    • Various types of Schemes, Like A Item Free with B Item Etc.
    • Accounts Vouchers & Cheque Printing
    • Receipt/ Payment Advice
    • Sales / Purchase Invoice, Estimate A7 Challan
    • Sale / Purchase Return Replacement & Price Difference
    • Debit Note/ Credit Note
    • Sales Orders / Purchase Order
    • Bank Pay in Slip & TDS Certificate
    • Stock Transfer Memo
    • Delivery Note, Goods Receipt Note & Dispatch Summary

    Fully User-Configurable Invoicing

    • Vat Invoicing Tax (Tax / Retail)
    • Tax Inclusive, Exclusive & MRP Billing
    • Multiple –taxes in Single Invoice
    • Manufacturing / Trading Excise Invoice
    • Export Invoice & Packaging Slip
    • Option for Pre-printed Stationary
    • Self-Designable Invoice Format

    Taxation Reports / Registers

    • Sales Tax / Purchase Tax Summary
    • Sales Tax Account Registers & Vat Returns
    • Sales Tax Forms Receivable / Issuable & Reminders
    • Service Tax, F.B.T. T.D.S, T.C.S Excise, Cess & H.E. Cess
    • Party Wise Vat Summaries
    • Check List
    • Cash Flow, Funds Flow & Ratio Analysis
    • Budgets / Targets / Credit Limits
    • Online Graph, SMS & E-mail
    • Any Report Export to Word & Excel
    • Sales / Purchase Analysis
    • Gross Profit Analysis
    • Financial, Expenses & Budget Analysis
    • Operator Wise Powers & Boundations with Operator Log Book
    • Smart Vat Patch no Need to Update software
    • User–Definable Warning Alarms & Colorful Indication
    • Year-Wise Data Backup and Restore
    • Data Export to Word / Excel / Text File
    • Draft Mode & GUI Printing
    • Last Year Comparison with Various Reports
    • Bird’s Eye View of Accounts
    • Powerful Query System
    • Credit Limit in Amount, Bill & Days with Stop Billing Facility
    • User Definable Hot Keys
    • Data Security with Self Backup & Carbon Copy system
    • Sales/Purchase, Bank, Ledger & Data Freezing on any Date
    • Auto recovery of Bill for unsaved bill due to Power Off
    • Attached with Hospital software & work on their guidelines
    • Any Report Printing from anywhere
    • Single User & Multi User
    • 100% Data Security & Accuracy
    • Tried & Tested (100% Error Free)
    • Multi-Currency, Unit, Godown & Financial Years Facility
    • Calculator & Cash Return Adviser
    • Month Calendar with Appointment Dairy & Note Pad
    • Supplier, Customers & Personal Directory
    • Telephone Book Envelope & Labels Printing
    • Hot Keys for Switch Over from one Report to Another
    • software / Operator/ Company Password & Boundations
    • Data Security with Self Backup & Carbon Copy System
    • Sale / Purchase, Bank Ledger & Data Freezing on any Date
    • Any Report Printing from Anywhere

    Comprehensive Financial Accounting

    • All Book of Accounts & Final Results
    • Balance Sheet with Various Schedules
    • Configurable Sales & Purchase Registers
    • Outstanding Reports and Analysis
    • Configurable Payment Reminder Letters
    • Configurable Statement of A/c
    • Interest Calculation & Bank Re-conciliation
    • Depreciation Chart (as per Co. Act / it Act)
    • Cost Centers with Grouping
    • Funds Planning / Bank Planning
    • Post Dated Cheques Facility
    • Voucher Approval System
    • All Books of Inventory
    • Brand, Group & Category Wise Inventory
    • Stock Valuation on Multiple Methods
    • Item Wise Gross Profit
    • Primary and Alternative Unit for Each Item
    • Party-wise Price Structure for Items / Groups
    • Multiple Prices Lists of Items
    • Sales & Purchase Order Processing
    • Batch / MRP / Size / Shade / Reference / Serial No. Wise Inventory

    Business Boosters

    Attraction About Marg

    Relative Products

    What is the need for computerization?

    In today’s scenario with the increasing inventory it is very difficult to keep a count of all stocks and accounts. It is also difficult to remember debtors and creditors and its outstanding’s. Computerization is the only way to keep a track of inventory and accounting.

    Will this help in stopping pilferage’s?

    When the staff comes to know that the store is computerized and the owner has all the knowledge of stocks and cash, the chances of pilferage’s reduces drastically.The best example is when in a store sign board of “You are under CC TV surveillance” is mentioned then there are very few chances of people doing any mischief’s. There is a general thought in owners mind that almost 3-4% stocks are pilfer aged, with the help of computerization this 3-4% can be saved.

    Will computerization help increase my SALES?

    Yes surely, with the help of computerization speed of billing increases by many folds and the customer now-a-days has more faith in computerized bill as the general thought is that if the bill is computerized then the rates and the products they are buying are genuine.

    Why only MARG for my business?

    MARG is an ISO 9001-2008 certified India’s one of the most leading integrated software companies with trade specific software solution for Retailers, Distributors, Manufacturers, Supply Chain, Retail Chain & Erp.

    Marg has 1500 setups to customize the software it according to your requirements.We have 6 Lacks plus satisfied customers with the help of our highly skilled global workforce consisting of 150 employees in head office and more than 1,500 service station employees in 586 cities of India with 370 exclusive support centers.

    Customer Review

    Our Clients


    Humanwell Healthcare, PuraCap Acquire Epic Pharma – Contract Pharma #bsp #pharma

    #epic pharma


    Related Breaking News

    Humanwell Healthcare Group and PuraCap Pharmaceutical have acquired Epic Pharma for $550 million. The acquisition will further establish Humanwell and PuraCap in the U.S. generics market and expand their existing commercial and manufacturing capabilities.

    The acquisition of Epic will provide a robust generic product portfolio, which includes tablets, 2-piece capsules and powder dosage form products as well as a future product portfolio that will include a series of controlled drug substances. Humanwell and PuraCap will acquire Epic s balanced and diversified portfolio, which currently consists of 15 marketed generic products and a pipeline of 37 products, and this acquisition will complement PuraCap s own R D efforts by utilizing Epic s strengths in the manufacture and development of controlled drug substances and powder formulations. The Epic acquisition will also add a U.S. FDA DEA inspected GMP manufacturing footprint of 110,000 square feet in Laurelton, NY, and result in the addition of 215 employees to the Humanwell and PuraCap U.S. operations team.

    This acquisition continues to broaden our global investments consistent with our strategy for the creation of a truly global pharmaceutical company for Humanwell Healthcare Group, said Richard Wang, chairman, Humanwell Healthcare Group.

    This acquisition is a major step in the growth of our company. In addition to strong and growing OTC and branded business units in the U.S. this acquisition along with our recent acquisition of Blu Pharmaceutical and Blu Carib, firmly establishes Humanwell and PuraCap in the U.S. generic Rx pharmaceutical segment. The PuraCap U.S. footprint continues to expand our tablet, softgel, 2-piece capsules, cream, and powder product portfolio, said Dahai Guo, chief executive officer, PuraCap and president, Humanwell USA.

    Breaking News


    Online Exclusives


    Expert’s Opinion

    Pharma Consulting, LLC #pharmaceutical #companies #in #los #angeles

    #pharma consulting


    D2 Pharma Consulting LLC is a Life Sciences consulting firm comprised of accomplished industry professionals who provide hands on expertise in all aspects of channel management including commercialization, distribution and compliance activities from launch to life cycle management for pharmaceutical products and devices.

    D2 provides strategic and tactical expertise to emerging and existing pharmaceuticals, biotech, and specialty organizations focusing on the individual client s business objectives.

    D2 steam of consultants will provide the vision necessary to ensure your organization s success operating in an evolving marketplace environment.

    Our philosophy is to be a strategic partner with our clients based on trust, integrity and impeccable work ethic resulting in value add to our customers. Our motto is Excellence Through Teamwork.

    more info

    Intelligent Pharma #inspire #pharma

    #pharma software


    Intelligent Pharma is awarded with the Premio Caracter Empresa to Innovation in Catalunya
    Barcelona, Spain, 9 th May, 2016

    Intelligent Pharma has been recognized once more for its innovation capacity by CaixaBank . the Spanish Confederation of Business Organizations (CEOE), and Foment del Treball . The Innovation category of the Premio Caracter Empresa awards recognizes the best companies with outstanding projects, competitive advantages, and growth potential. Intelligent Pharma, from its headquarters at the PCB, has developed 10 leading technologies in computational chemistry.
    For us, this award represents an important recognition for our day-to-day work. At Intelligent Pharma, we are working intensively on the research and development of new technologies that can help cure major diseases afflicting our society. Awards like this help us know that we are on the right track said Dr. Ignasi Belda, CEO and founder of Intelligent Pharma.

    Intelligent Pharma receives Marie Curie Training Award

    Intelligent Pharma is participating in a 3.8M Marie Curie Innovative Training Network (ITN) called TRAIN Tribbles Research and Innovation Network . Led by Dr. Ender Kiss-Toth (The University of Sheffield), the consortium includes companies and institutions from the UK, Spain, Germany, France, The Netherlands, Portugal, and Hungary. The work in this program will be undertaken by 15 PhD students who will investigate how dysregulated innate immune responses and metabolism promote the development and progression of cancer.


    Intelligent Pharma’s goal is to be your computational chemistry and bioinformatics team, working with you to develop computational chemistry tasks relevant to your drug discovery project. We can also act as a support team for your computational department on the development processes you already have in place.

    Intelligent Pharma offers advanced software development solutions for companies and institutions working in life sciences including the pharmaceutical, biotechnological, cosmetic and nutritional fields.

    Intelligent Pharma provides you with software solutions to manage the acquired information and knowledge of your organization.

    Tower Pharma Consulting #bsp #pharma

    #pharma consulting


    Welcome to Tower Pharma Consulting

    We are a pharmaceutical consultancy that specialises in pharmaceutical product development and drug delivery. Based in Vienna, Austria, we provide a variety of scientific, technical and project management services to both large and small pharmaceutical/biotech companies and government agencies.

    Services Looking for formulation expertise or seeking an independent evaluation?
    More Info

    The consultancy was founded by
    Dr. Louise Rosenmayr-Templeton,
    a pharmacist with over 18 years’ experience in the fields of pharmaceutical research and development as well as project management.

    The consultancy’s key strengths lie in the following areas:

    • Technology evaluation & benchmarking
    • Development of formulation strategies
    • Formulation expertise & problem-solving
    • Service provider identification & evaluation
    • Management of outsourced projects

    These strengths, coupled with our international experience, enable us to provide tailor-made services for our clients.

    So whether your challenge relates to technology evaluation, development of formulation strategies or finding the right contract service provider, let Tower Pharma Consulting guide you to the solution.

    News Workshop on Successful Early Stage Development of Pharmaceuticals
    More Info

    ISIS Pharma Consulting #pharma #software

    #pharma consulting


    Interim Management. Senior Interim QA and Regulatory Affairs roles undertaken. continue reading Quality. Quality Assurance Consultation continue reading Regulatory Affairs. Regulatory Affairs Consultation, Conducting Regulatory Due Diligence audits, Preparation of Expert Reports continue reading Medical Devices. Provision of QA, Gaining Quality system accreditation eg ISO 9001 continue reading

    Welcome to ISIS Pharma Consulting

    Isis Pharma Consulting offers a unique combination of Quality Assurance and Regulatory Affairs expertise, supported by considerable senior management experience. We offer interim management and bespoke consultancy services.

    The company is headed by Indira Walker who is ably assisted by a team of associates. All our associates have a wide range of specialisms including Interim Management, Auditing, Quality and Regulatory Affairs. All team members are expert in developing compliant operationally effective and commercially sensible solutions for your business.

    We believe we offer outstanding customer service, immersing ourselves in the client organisation with dedication and enthusiasm.

    Copyright ISIS Pharma Consulting. All Rights Reserved.

    Pharmaceutical – Healthcare Market Research #jobs #in #pharmaceutical #companies

    #pharma marketing research


    MAXimum Research, Inc. – Your Market Research Professionals

    Here at MAXimum Research, we can reach those doctors others find hard or impossible to reach.


    We currently have a medical database containing over one million healthcare professionals, made up of hospitals, MCOs, nurses, and physicians.

    Our medical interviewers are Elite Interviewers who have at least one year of experience with a background in Pharma. They are trained on recruiting and/or interviewing all types of healthcare workers, from Medical and Pharmacy Directors to nurses and lab technicians, as well as patients with specific ailments, their caretakers, and general consumers.

    The following are some of the healthcare facilities and organizations in which MAXimum Research, inc. has had extensive experience:

    • Hospitals (small, medium and large)
    • Pharmacies (retail and independent)
    • Offices (Private practice or hospital based)
    • Pharmaceutical Companies
    • Clinics and Laboratories
    • Managed Care Organizations
    • Insurance Organizations (medical, dental & vision)
    • Government Healthcare
    • Medical Associations

    Mission Statement

    “MAXimum Research gives each and every client the personal attention and service they deserve, quickly, accurately and within budget.”
    – Robert A. Malmud President

    “Like” Us on your facebook page and/or Follow Us in LinkedIn to receive future MAXimum Research Inc. related news, information and survey invitations, as well as facts relating to the Market Research Industry.

    About OPIR #pharmaceutical #industry #overview #2013

    #pharmaceutical industry research


    About OPIR


    The Office of Pharmaceutical Industry Research (OPIR) was established in January 1999 by the Japan Pharmaceutical Manufacturers Association (JPMA). The OPIR has its mission to analyze the internal and external environments of the Japanese pharmaceutical industry and the mid-and-long-term issues it faces, and to make public policy recommendations based on its research.


    Through its research, the OPIR aims to develop an economic and social framework which contributes to the swift and continuous provision of innovative and efficacious medicines with appropriate prices. The framework should enhance access to and proper use of the medicines by healthcare consumers. OPIR research is also expected to contribute to raising public awareness of the importance of and the social role of the pharmaceutical industry.

    OPIR serves as an open laboratory for research and policy recommendations and development of human resources through friendly competition. OPIR proactively promotes its research including outside research collaboration and external research contracts.


    Research results already published and ongoing research themes in recent years

    Policy for Innovation

    • Strengthening the global competitiveness of drug discovery and basic technology in emerging areas
    • Strength of basic research for drug discovery in Japan
    • Current situation of personalized medicine and trends in pharmaceutical industry
    • Public support of R 2015 Office of Pharmaceutical Industry Research. all rights reserved.

    Pharmaceutical Industry Research Guide – Baker Library #pharmaceutical #company #list

    #pharmaceutical industry research



    A great starting place for research on the pharmaceuticals industry; this guide points to the best resources available to the HBS community.

    Ernst & Young Industries: Pharmaceuticals
    Includes free industry reports, surveys of executives, and discussions of critical issues.

    Frost & Sullivan
    Analyst reports on trends, issues, and market-related topics.

    Gale Virtual Reference Library .
    Include Strategies in Drug Discovery and Evaluation and general background on other pharmaceutical related topics. (Select the Medicine section.)

    Find current and historical overviews related to pharmaceuticals such as nanotechnology tools in pharmaceutical R lists new approvals and drugs in trial.

    Provides detailed drug (i.e. chemical, pharmacological and pharmaceutical) data with comprehensive drug target (i.e. sequence, structure, and pathway) information.

    Pharmaceutical Executive
    Gives sales, R
    /* 728×90, создано 05.02.11 */
    google_ad_slot = “6127977750”;
    google_ad_width = 670;
    google_ad_height = 90;

    Business Sector #pharma #analytics

    #pharma marketing



    Healthcare Pharmaceutical

    Promozoo provides specialist marketing for the highly regulated healthcare and pharmaceutical sectors. Our skills bring together medical, marketing and innovative media to develop the optimum strategy for your brand. We work with some of the world’s leading pharmaceutical companies.

    Our specialist services include:

    • Mass media campaign planning and placement
    • Creative design
    • Web and app development
    • E-detailers and e-learning
    • Video and brand broadcast production
    • Livestreaming and webinar events
    • Print management

    Business to Business (B2B)

    Business-to-business (B2B) and business-to-consumer (B2C) marketing are very different and require different marketing approaches. Our B2B strategies are tailored to help your target audience determine the value of your product or service through education, events, promotions, testimonials, and other activities that build brand engagement and loyalty.

    Our B2B marketing strategies are based on:

    • Building relationships
    • Focused target markets
    • Educational and awareness building activities
    • Encouraging rational buying decisions based on business value

    Business to Consumer (B2C)

    Consumers make buying decisions based on status, security, and quality. Our proven B2C marketing strategies will help convert occasional, casual shoppers into regular consumers with lasting brand loyalty. Our aim is to optimise the consumer’s emotional perspective about their purchases and drive revenue for your brand.

    Our B2C services include:

    • Brand creation and identity
    • Mass media campaign planning and placement
    • Video and brand broadcast production
    • Email Campaign planning, creation and execution
    • Merchandising and point of purchase activities
    • Ecommerce websites
    • Specialist app development

    Let’s work together

    Pharma MR wins in Maine and DC but loses in Vermont #gea #pharma #systems

    #pharmaceutical market research


    Pharma MR wins in Maine and DC but loses in Vermont

    An MRA round-up of legislative and regulatory victories and defeats

    Recent wins for pharmaceutical marketing research in Maine and DC leave only West Virginia and Vermont as the jurisdictions currently restricting or prohibiting research with physicians and healthcare professionals. Although hope remains that West Virginia might come around, the door has closed on pharmaceutical marketing research in Vermont for the foreseeable future. These changes stemmed fundamentally from the enactment of the federal Physician Payments Sunshine Act as part of the 2010 Patient Protection and Affordable Care Act (PPACA) — a law that, thanks to lobbying by MRA, excludes marketing research incentives from its reporting requirements for payments to physicians from pharmaceutical and medical device manufacturers.

    Existing law in Maine (22 M.R.S.A. §2698-A ) required that pharmaceutical drug manufacturers annually report on their marketing expenses to Maine residents, specifically to Maine physicians. Although the law made no reference to survey research, the implementing regulations did:

    However, on July 8, Governor Paul LePage (R) signed H.P. 530 into law as Public Law Chapter 461, repealing the pharmaceutical marketing reporting provisions .

    The repeal is effective September 28, 2011. How permanent will this repeal really be? According to Maine Rep. Sharon Anglin Treat (D-79), Executive Director of the National Legislative Association on Prescription Drug Prices (NLARx). “In terms of next steps, it would be foolish to try to reverse these repeals with the current Legislature and governor. If Maine people want a different result (and understand what has happened) then they will elect different people the next time around.”

    The District of Columbia
    Title III of the AccessRx Act (implemented in Chapter 18, Title 22 ) set annual reporting requirements for the marketing costs of manufacturers and labelers of prescription drugs. Although the law made no mention of marketing research, the regulations specifically mentioned the reporting of direct or indirect payments for participation in marketing research. This led most pharmaceutical manufacturers and labelers to avoid marketing research with DC physicians.

    MRA had campaigned to exclude marketing research incentives from the DC regulations for several years. On August 4, 2011, thanks to the dogged efforts of MRA volunteer Rick Seale (Shugoll Research), MRA’s lobbying campaign since 2007, and a contract lobbyist hired by CASRO, CASRO was able to share the news that the DC Board of Pharmacy had approved an exclusion for payments to health care providers for participation in marketing research, if: “(i) the market research is conducted by an independent survey research organization; (ii) the pharmaceutical client does not know the identity of the practitioners who participate in the research; and (iii) the payments are determined and made directly by the survey research organization.”

    Because the reporting requirements in DC are on an annual basis, this new exclusion for marketing research payments is effective immediately.

    Going in the opposite policy direction, the state of Vermont has now explicitly prohibited marketing research incentives for physicians who participate in pharmaceutical research. Existing law was unclear on how it impacted marketing research incentives. Although the Attorney General’s office hinted that it did not think the law applied to marketing research, pharmaceutical manufacturers already avoided all marketing research with Vermont health care providers.

    Unfortunately, as MRA predicted. Vermont Governor Peter Shumlin (D) signed S.B. 108 into law as Public Act 51 on May 26. The new law explicitly outlaws incentives for health care providers participating in pharmaceutical marketing research, stating: “no manufacturer or other entity on behalf of a manufacturer shall provide any fee, payment, subsidy, or other economic benefit to a health care provider in connection with the provider’s participation in research.”

    As explained above, this does not change the effective status quo — no pharmaceutical marketing research with Vermont health care providers was happening anyhow. The anti-pharmaceutical activists in the Vermont House who spiked our efforts to exclude marketing research will likely ensure that this law does not get overturned or fixed any time soon.

    The Battle Continues
    With the legal ambiguity in Vermont resolved to the detriment of marketing research, this leaves Vermont and West Virginia as the only states that still restrict pharmaceutical marketing research incentives for physicians. While the federal Sunshine Act does not come into effect in 2013 (assuming it is not overturned before then), it has already discouraged most states from pursuing similar reporting payment disclosure laws (which could end up pre-empted by the Act) and directly led to the repeal of Maine’s superfluous law.

    MRA continues to campaign regardless against other state legislation that could impede pharmaceutical marketing research, including: H.B. 45 in Alaska; A.B. 1636. S.B. 212 and A.B. 5978 in New York; S.B. 79 in Ohio; and H.B. 1544 and S.B. 515 in Massachusetts.

    Howard Fienberg

    Founded in 1957 and based in Washington, the Marketing Research Association is the leading and largest U.S. association of the opinion and marketing research profession, which delivers insights and strategies to help guide the decisions of companies providing products and services to consumers and businesses.

    Membership Benefits

    • MRA’s total reinvestment of all revenues back into our profession directly enriches your career and those of other researchers like you.
    • Dozens of live educational webinars + archive
    • Regional Chapter + national networking opportunities
    • Alert! magazine, MRA Update newsletter + archives
    • Discounts on Insights & Strategies + Corporate Researchers Conferences
    • Discounts on Blue Book Marketing Research Services and Focus Group Facility Listings
    • Members-only legal guidance library
    • Full-time lobbyist representing MR

    Contact Us

    Novartis – sales performance, data and rankings – Top Pharma List #pharmaceutical #firms

    #pharma company



    Data by GlobalData

    GlobalData is the premier source of research and consulting solutions for the pharmaceutical and medical device industries. With the combined expertise of more than 600 researchers, market analysts and consultants, we deliver high-quality, accurate and transparent industry insight that helps our clients to achieve growth and increase business value.

    To find out more about how our research and consulting solutions can help you, please visit

    Featured jobs

    Director, Scientific Services Great salary and benefits
    ID Search Selection

    Principal Medical Writer Great salary and benefits
    ID Search Selection

    Director, Scientific Services 80 – 100,000 or more according to skills and experience + benefits
    Media Contacts (Recruitment Consu.

    At Weber Shandwick, engagement has always been the cornerstone of health communications.We make health matter. Health is a basic human.

    Slide Deck: Kinetic: A new approach shaping the future of advisory boards How many times have we attended meetings that have little direction, or no clear objectives and left feeling disinterested and disengaged? Our “Kinetic” consulting approach is set to change all.

    Alzheimer’s disease: reviewing the immediate treatment horizon Account Manager Stuart Goodman takes a look at some of the promising categories of Phase 3 treatments that could soon be available to patients with Alzheimer’s disease.

    Anthill awarded full Veeva certification We are proud to announce we have been certified level 4 Veeva multichannel content partner.

    Quick links